Page 1 of 63 
 [STUDY_ID_REMOVED]  
 
A-TREAT Protocol Version 3.5  
 
2018 -05-07 
  
Page 2 of 63 
                                                                                                                                                                                                                                                                                                                                                           
 
 
 
American Trial Using  Tranexamic 
Acid in Thrombocytopenia   
(A-TREAT ) 
 
 
A randomized , controlled trial evaluating the safety 
and efficacy of tranexamic  acid in patients with 
hematologic malignancies and severe 
thrombocytop enia 
 
 
 
 
 
 
Version 2.0 23 September 2015     FDA IND Initial Submission  
Version 2.1  16 October 2015     FDA IND Amendment 1  
Version 2.2  21 October 2015     FDA IND Amendment 2  
   FDA IND 128032 approval 2015 -10-23 
Version 2. 3 6 January 2016  
Version 2.4  3 February  2016      FDA IND Amendment 3  
Version 2.5  7 March  2016   
Version 3.0  9 May 2016      DSMB Approved Version  
Version 3.1  13 June 2016      FDA IND Amendment 4  
Version 3.2  20 April 2017        FDA IND Amendment 5  
Version 3.3  26 June 2017      FDA IND Amendment 6  
Version 3.4   12 December 2017     FDA IND Amendment 7  
Version 3.5  07 May 2018      FDA IND Amendment 8  
 
 
 
  
Page 3 of 63 
 Approved by:      
Name:       Role:  Principal Investigator(s)  
Signature:   
  Date:   
     
     
     
     
     
     
     
     
     
     
     
     
     
Authorized by:     
Name:       Role:  DCC Principal Investigator  
Signature:   
  Date:   
 
  
Page 4 of 63 
 GENERAL INFORMATION  
 
This document provides in depth background information for the A-TREAT  trial. It also serves 
as a guidance document for the proper identification, treatment and maintenance of A-TREAT  
trial patients. This protocol should not be used as a guide for the treatment of patients not 
enrolled in the A-TREAT  clinical trial.   Every c are was taken in its drafting, but corrections or 
amendments may be necessary ; these will be circulated to  registered investigators in the trial, 
but centers  entering patients for the first time are advised to contact the Data Coordinating 
Center (DCC) to confirm they have the most up to date version. Clinical problems relating to 
this trial should be referred to the relevant Principal Investigator.  
 
Contacts  
If you have any queries regarding this protocol, or the general conduct of the trial, please 
conta ct one of the following people:  
 
Principal Investigator s 
• Terry Gernsheimer, MD (University of Washington, Seattle Cancer Care Alliance , Fred 
Hutch inson Cancer Research Center ) 
• Susanne May, PhD  (University of Washington)  
• Darrell Triulzi, MD (University of Pittsburgh)  
• Nigel Key, MD (University of North Carolina)  
• Sherrill Slichter, MD (Bloodworks Northwest)  
 
Trial email : help@A -TREAT.org  
 
Compliance Statement  
The study will be conducted according to the protocol and in compliance with International 
Conference on Harmonization (ICH) Good Clinical Practice (GCP), Belmont Principles, and 
other applicable regulatory requirements. All identified study personnel will be trained to 
perform their roles and will carry out their responsibilities in accordance with ICH GCP 
guideline and clinic site SOPs.  
 
Funding Sources:  National Heart, Lung and Blood Institute of the National Institute of Health  
Data Coordinating Center: Susanne May, PhD  (University of Washington)  
 
Clinical Coordinating Center:  University of Washington  
 
Lead Trial Statistician(s): Susanne May, PhD  
 
Trial Sites IRBs of Record:  
• University of Washington  IRB 
• University of Pittsburgh IRB  
• University of North Carolina IRB   
Page 5 of 63 
 PROTOCOL SYNOPSIS  
Despite major advances in optimizing platelet transfusion therapy, bleeding remains a problem 
in patients with thrombocytopenia due to chemotherapy induced marrow aplasia and 
hematopoietic stem cell disorders.1  Baseline level of bleeding does not appear to be affected  
by increasing the platelet transfusion threshold2,3 and does not appear to be dependent on the 
platelet count when it is above 5,000/ l.  In the PLADO (Platelet Dose) Trial of 1272 patients, 
WHO grade 2 bleeding occurred in approximately 70% of all subj ects regardless of platelet 
dose transfused prophylactically for patients with platelet counts of ≤10,000/µL4. Withholding 
transfusion may lead to serious and fatal bleeding5. In a 600 patient trial of therapeutic vs. 
prophylactic platelet transfusion (T OPPS)6, bleeding remained a common event. Maintenance 
of a safe platelet count may be difficult due to shortened platelet survival in severely 
thrombocytopenic and critically ill patients.7 Patients  who are  refractory to platelet transfusion 
may require expensive and difficult to obtain matched platelets to prevent serious bleeding. 
Maintenance of the platelet count above a prescribed trigger in outpatients can require daily 
laboratory work and frequent  visits to the clinic for transfusions . 
 
Epsilon Aminocaproic Acid (EACA) and Tranexamic Acid (TXA) are inhibitors of fibrinolysis 
that can b e given either intravenously or orally. Inhibitors of fibrinolysis have been used for 
many years to prevent and treat bl eeding due to fibrinolysis intra - and postoperatively8 and 
have been shown to be useful in in patients with platelet function and coagulation defects such 
as hemophilia9. Reports of the use of these agents to prevent or treat bleeding in 
thrombocytopenic  patients have been encouraging10,11,12 and suggest that in many patients 
bleeding can be prevented or stopped. Such anecdotal, retrospective single center reports 
lead many physicians to prescribe EACA  or TXA to prevent or treat bleeding in 
thrombocytopenic patients refractory to platelet transfusions;  however , lack of evidence of 
efficacy and safety prevent its use from becoming standard of ca re.  
 
The results of this study will change practice by providing evidence as to whether or not the 
fibrinolytic agent TXA is an effective and safe t reatment when used as an adjunct to platelet 
transfusion therapy to prevent bleeding in patients with hypoproliferative thrombocytopenia. A 
safe treatment to decrease bleeding and transfusion requirements in these patients would 
greatly improve patient out comes and quality of life, and have a major health economic 
impact.  
 
Objectives  
The purpose of this study is to compare the incidences of bleeding and thrombosis , and the 
transfusion requirements in patients randomized to receive TXA or a placebo for 
hypoproliferative thrombocytopenia secondary to primary marrow disorders, chemotherapy, 
immunotherapy, radiation and/or hematopoietic stem cell transplant .  
 
Study Design  
Double blind, randomized, placebo controlled trial.  Subjects will be screened for eligibility by 
trained study staff after being identified by primary providers as likely to have platelet counts of 
≤10,000/ l for ≥5 days.  Bleeding and thrombotic assessments will be performed daily on 
inpatient  subjects via chart review,  subject interview and physical examination. Outpatient 
subjects  will maintain a daily diary and be seen at least weekly in clinic.  
 
 
 
 
 
 
 
 
Page 6 of 63 
 Table of Contents  
1. Summary  ................................ ................................ ................................ ............................  8 
 Figure 1: Trial Entry, Randomization, Treatment and Monitoring Flow Diagram  .................  12 
2. Background  ................................ ................................ ................................ .....................  12 
3. Endpoints  ................................ ................................ ................................ .........................  13 
3.1: Primary Endpoint  ................................ ................................ ................................ . 13 
3.2: Secondary Endpoints  ................................ ................................ ............................  13 
3.3: Supportive and Exploratory Efficacy Endpoints  ................................ ........................  13 
3.4: Safety Endpoints  ................................ ................................ ................................ .. 14 
3.5: Sub -group Analyses  ................................ ................................ .............................  14 
4. Target Patient Populations  ................................ ................................ .............................  14 
4.1: Inclusion Criteria  ................................ ................................ ................................ .. 14 
4.2: Exclusion Criteria  ................................ ................................ ................................ ........  14 
5. Trial Enrollment  ................................ ................................ ................................ ...............  15 
5.1: Screening and Recruitment  ................................ ................................ ...................  15 
5.2: Stratification and Randomization  ................................ ................................ .................  15 
5.3: Enrollment Period  ................................ ................................ ................................ ........  16 
6. Interventions  ................................ ................................ ................................ ....................  16 
6.1: Study Drug  ................................ ................................ ................................ ..........  16 
6.2: Transfusion Practice  ................................ ................................ .............................  16 
6.3: Stopping of Study Drug  ................................ ................................ ...............................  17 
6.4: Temporary Discontinuation of Study Drug  ................................ ..............................  17 
6.5: Dose Adjustments for Renal Insufficiency  ................................ ...............................  17 
6.6: Other Treatment Considerations  ................................ ................................ ..................  18 
7. Study Drug Information  ................................ ................................ ................................ ... 18 
7.1: Masking of Study Drug  ................................ ................................ .........................  18 
7.2: Administration of Study Drug  ................................ ................................ .......................  18 
8. Study Visit Procedures and Schedule  ................................ ................................ ............  19 
8.1: Day of Enrollment  ................................ ................................ ................................  19 
8.2: Days Between Enrollment and Randomization  ................................ ............................  20 
8.3: Day of Randomization  ................................ ................................ ..........................  20 
8.4: Days Between Randomization  and Activation  ................................ ..........................  21 
8.5: Activation  ................................ ................................ ................................ ............  22 
8.6: End of Treatment  ................................ ................................ ................................ .........  26 
8.7: EOT to D14 post Discontinuation of Study Drug  ................................ ......................  26 
8.8: Follow Up  ................................ ................................ ................................ ............  26 
Table  2: Study Assessments Calendar  ................................ ................................ ...............  27 
9. Adverse Event Reporting  ................................ ................................ ................................  29 
Figure 3: Adverse Event Definitions  ................................ ................................ ..............  29 
9.1: Expected Adverse Events  ................................ ................................ ............................  30 
9.2: Pregnancy  and Nursing  ................................ ................................ ...............................  31 
10. Hemostatic/Bleeding Assessments  ................................ ................................ .............  31 
10.1: Inpatient Subjects  ................................ ................................ ..............................  32 
10.2: Outpatient Subjects  ................................ ................................ ................................ ... 32 
11. Safety  Assessments  ................................ ................................ ................................ ...... 32 
11.1: Thrombotic Assessments  ................................ ................................ ....................  32 
11.2: Ocular Assessments  ................................ ................................ ................................ .. 33 
12. Loss to Follow Up  ................................ ................................ ................................ ..........  33 
12.1: Death  ................................ ................................ ................................ ................  33 
12.2: Withdrawals  ................................ ................................ ................................ ...............  33 
13. End of Study  ................................ ................................ ................................ ..................  34 
Page 7 of 63 
 14. Statistical Considerations  ................................ ................................ .............................  34 
14.1: Rationale and Objectives  ................................ ................................ ....................  34 
14.2: Randomization  ................................ ................................ ................................ ..........  34 
14.3: Analysis Populations  ................................ ................................ ...........................  34 
14.4: Competing Risks  ................................ ................................ ................................ ....... 35 
14.5: Statistical Analysis Models  ................................ ................................ ........................  36 
14.6: Sample Size and Precision of Statistical Inference  ................................ .................  37 
14.7: Feasibility of Recruitment  ................................ ................................ ..........................  38 
15. Trial Monitoring  ................................ ................................ ................................ .............  39 
15.1: Clinical Site Monitoring  ................................ ................................ .......................  39 
15.2: Direct Access to Data  ................................ ................................ ................................  39 
15.3: Audits and Inspections  ................................ ................................ .......................  39 
15.4: Source Data Verification  ................................ ................................ ............................  39 
15.5: Quality Assurance and Quality Control of Data  ................................ ..........................  39 
15.6: Confidenti ality ................................ ................................ ................................ .... 40 
15.7: Ethical Conduct of the Study  ................................ ................................ .....................  40 
16. Records and Reports  ................................ ................................ ................................ .... 40 
16.1: Case Report Forms  ................................ ................................ .............................  40 
16.2: Record Retention ................................ ................................ ................................ ....... 41 
16.3: Data Management  ................................ ................................ ................................ ..... 41 
Table  4: Definitions of Causality/Attribution  ................................ ................................ ........  42 
Figure 5: Investigator Assessment of Adverse Events Flowchart  ................................ ........  43 
17. Institutional Review Board (IRB)  ................................ ................................ ..................  44 
18. Trial Committees  ................................ ................................ ................................ ...........  44 
18.1: Trial Steering Committee (TSC)  ................................ ................................ ...........  44 
18.2: Data and Safety Monitoring Board (DSMB)  ................................ ...............................  44 
Appendix 1: Tranexamic Acid and Epsilon Aminocaproic Acid Studies  .........................  45 
Appendix 2: WH O Grading System  ................................ ................................ ....................  54 
Appendix 3: A-TREAT  Telephone Script : Long -Term Follow -Up ................................ ..... 59 
Citations : …………………………………………………………………………………………. .60 
  
 
 
 
 
  
Page 8 of 63 
 ABBREVIATIONS AND GLOSSARY  
ADL Activities of Daily Living  
AE Adverse E vent 
AR Adverse R eaction  
CF Consent F orm 
CRF Case Report Form  
CTCAE  Common Toxicology Criteria for Adverse Events  
D5W  5% Dextrose in Water  
DCC  Data Coordinating Center  
DCF Data Clarification Form  
DDA VP Desmopressin A cetate  
DIC Disseminated Intravascular Coagulation  
DSMB  Data and Safety Monitoring Board  
EACA  Epsilon Aminocaproic Acid  
DMS  Data Management System  
FDA Food and Drug Administration  
GCP  Good Clinical Practice  
HR Hour  
HIV Human Immunodeficiency V irus 
HTLV  Human T -lymphotropic V irus 
HUS  Hemolytic Uremic S yndrome  
IB Investigator’s Brochure  
IRB Institutional Review Board  
ISRCTN  International Standard Randomized Controlled Trial N umber  
ITP Immune T hrombocytopenia  
IV Intravenous  
LAR Legally Authorized Representative  
NHLBI  National Heart, Lung and Blood Institute  
PCC  Prothrombin Complex C oncentrate  
PI Principal Investigator  
PIS Patient I nformation Sheet  
PO Oral 
Q Every  
RCT Randomized Controlled T rial 
RN Registered Nurse  
SAE Serious A dverse Event 
SAR  Serious Adverse Reaction  
SOC  Standard of Care 
SCT Stem Cell Transplant  
SOP  Standard Operating Procedure  
SOS  Sinusoidal Obstructive Syndrome  
SSA Site Specific Assessment  
Study Drug  Tranexamic Acid or matching placebo  
SUSAR  Suspected Unexpected Serious Adverse Reaction  
TSC Trial Steering Committee  
TTP Thrombotic Thrombocytopenic P urpura  
TXA Tranexamic Acid  
UAR  Unexpected A dverse Reaction  
VOD  Veno -occlusive Disease  
VTE Venous Thromboembolism  
WBC  White Blood Cell  
WBD  Whole Blood Derived  
WHO  World Health Organization  
Page 9 of 63 
 1. SUMMARY  
Name of Sponsors:  
National Heart, Lung and Blood Institute, National Institutes of Health  
 
Name of Investigational Products:  
Tranexamic  Acid ( TXA) 
 
Name of Active Ingredient:  
Tranexamic  Acid 
 
Title of Study:  
A-TREAT : American Trial Using  Tranexamic  Acid in Thrombocytopenia  
 
Study Centers:  
University of Washington (UW)  
University of Nort h Carolina (UNC)  
University of Pittsburgh (UP)  
 
Principal Investigators:  
Terry Gernsheimer, MD  (University of Washington)  
Sherrill J. Slichter, MD  (Bloodworks Northwest)  
Nigel Key, MD  (University of North Carolina)  
Darrell Triulzi, MD (University of Pittsburgh)  
Susanne May, PhD  (University of Washington)  
 
Studied Period (4 years):  
Estimated date f irst subject enrolled: Q1 201 6 
Estimated date last subject completed: Q4 201 9 
 Phase of development: Phase 3  
 
Objectives:  
The purpose of this study is to conduct a prospective, randomized, blinded, placebo controlled trial to 
evaluate the usefulness of antifibrinolytic therapy with tranexamic  acid in preventing bleeding in 
patients who are thrombocytopenic due to primary bone marrow disor ders or chemotherapy, 
immunotherapy , and/or radiation therapy. The results of this study will change practice by providing 
evidence as to whether or not TXA is effective and safe treatment when used as an adjunct to platelet 
transfusion therapy in the thrombocytopenic patient.  
Primary Objectives:  
• Assess  whether TXA reduces bleeding in patients with thrombocytopenia due to aplasia, 
chemotherapy , stem cell transp lantation for hematologic disorders.  
• Obtain data on the safety of TXA in thrombocytopenic patients.  
• Assess whether TXA therapy can reduce the number of prophylactic platelet transfusion s in 
thrombocytopenic patients undergoing treatment with chemotherapy o r stem cell 
transplantation.  
Secondary Objectives:  
• To examine AEs,  and clinical laboratory parameters related to treatment with TXA.  
• To examine platelet efficacy endpoints in vivo including spontaneous bleeding rates, platelet 
count increments (Cl) , and corrected count increments (CCI).  
Methodology:  
Randomized, double -blind, placebo controlled, superiority trial enrolling thrombocytopenic adult 
patients with aplasia or hematologic malignancies receiving intensive chemotherapy, radiation , and/or 
Page 10 of 63 
 hematopoietic stem cell transplantation. Subjects will be  randomized in a 1:1 ratio to either the 
antifibrinolytic TXA or placebo (oral or intravenous [IV]) treatment arms when their platelet count falls 
below 50,000/l, and is expected by their primary provider to have platelet counts of ≤10,000/ l for ≥5 
days.  When a randomized subject’s platelet count falls to < 30 ,000/l, the subject will be activated to 
begin their assigned study drug. Treatment with the study drug will continue until the platelet count is ≥ 
30,000/l for 46 hours without platelet transfusion support, until a maximum of 30 days after treatment 
activation, or until the subject meets other protocol specified safety criteria for stopping study drug, 
whichever comes first.   Data collection for primary efficacy endpoints will continue for 30 days after 
activation of study drug, with additional long term follow -up at 14 and 30  days and 120 days post 
activation of study drug. A bleeding assessment f orm will be completed daily by a trained member of 
the research staff for each day a subject is hospitalized. Outpatient subjects (including inpatient 
subjects that are discharged home prior to completion of the trial follow -up period) will complete a dail y 
Self-Assessment Bleeding Diary and a trained member of the research staff will review the subject’s 
diary, records of all clinic visits for transfusions, bleeding and adverse events at least once a week.  
Adverse event data will be collected for 30 days after receipt of last dose of study drug.  
 
Estimated Number of Subjects Screened: Approximately  2,500 subjects screened  
 
Maximum Number of Subjects Enrolled: Approximately 360 subjects will be enrolled at 3 U.S. study 
sites to obtain 330 activated subjec ts. 
 
Diagnosis and Main Criteria for Inclusion/Exclusion:  
Inclusion criteria  (all must be met) : 
• Must be  ≥ 18 y ears of age  
• Confirmed diagnosis of a hematologic malignancy  or aplasia  
• Undergoing or planned chemotherapy , immunotherapy,  or hemat opoietic stem cell 
transplantation  
• Anticipated to have hypoproliferative thrombocytopenia resulting in a platelet count of ≤ 
10,000/l for ≥ 5 days  
• Able to provide informed consent and comply with treatment and monitoring , or having a 
Legally Authorized Representative (LAR)  
 
Exclusion criteria  (none can be present) : 
• Diagnosis of acute promyelocytic leukemia undergoing induction chemotherapy  
• History of ITP, TTP or HUS  
• Subjects receiving L -aspar aginase as part of their current cycle of treatment  
• Subjects with a past history or current diagnosis of arterial or venous thromboembolic disease 
including  acute coronary syndrome , peripheral vascular disease and retinal arterial or venous 
thrombosis  (except when a prior history of central line thrombosis has resolved ) 
• Subjects with a diagnosis/previous history of sinusoidal obstruction syndrome (also called  
veno -occlusive disease)  
• Subjects receiving any pro -coagulant agents (e.g. DDAVP, recombinant Factor VIIa or 
Prothrombin Complex Concentrates (PCC) and/or an antifibrinolytic agent within 48 hours of 
enrollment, or with known hypercoagulable state  
• Known inherited or acquired bleeding disorder  including, but not limited to:  
o Acquired storage pool defi ciency  
o Paraproteinemia with platelet inhibition  
• Known inherited or acquired prothrombotic disorders , including  antiphospholipid syndrome.  
Those with lupus anticoagulant or positive antiphospholipid serology without thrombosis are 
not excluded.   
• Subjects r eceiving anticoagulant therapy or anti -platelet therapy  (except   when   receiving 
prophylactic anticoagulant or low dose aspirin therapy for prophylaxis only with a plan to 
discontinue when the platelet count falls below 50,000)  
• Patients with DIC according to the patient’s physician  
• Subjects with WHO Grade 2 bleeding or greater  within 48 hours prior to  activation  
• Subjects requiring a platelet transfusion threshold > 10 ,000/l at time  of randomization  
• Subjects with anuria (defined as urine output < 10mls/hr over 24 hours)   
• Subjects on dialysis  
• Subject s with creatinine ≥5.7mg/dL  
Page 11 of 63 
 • Subjects who are pregnant  or nursing  or unwilling to use contraception during and for 30 days 
after taking the study drug (both males and females)   
• Subjects enrolled in other trials involving platelet transfusions, anti -fibrinolytics, platelet growth 
factors or other pro -coagulant agents.  
• Known allergy to tranexamic  acid  
• Having been p reviously randomized in this study at any stage of their treatment  
• Subjects  who are unwilling to accept blood or blood component transfusions  
 
Drug Dosage, Schedule, and Mode of Administration:  
Inpatient subjects will receive TXA or placebo via oral (PO) or intravenous (IV) administration - the 
decision concerning route of administration  will be left to the discretion and documentation of the 
treating investigator  or treating physician . Outpatient subjects will receive TXA or placebo via oral 
administration.  
Dosing S chedule:   TXA, 1.0g IV or 1.3g PO every 8 hours  versus a placebo  equivalent every 8 hours  
(oral study drug supplied by a contracted investigational pharmaceutical company) . 
 
Duration of Treatment:  
Subjects will receive  study drug for up to 30 days  per methodology referenced above  and study specific 
follow -up will occur at 14 (+ 7 day window), 30 days post discontinuation of study drug  and 120   days 
post activation  of study drug .  Adverse events will be followed for 30 days after the last dose of st udy 
drug is taken.  
 
Criteria for Evaluation:  
Primary Efficacy Endpoints:  
• Proportion of patients with bleeding of WHO grade 2 or above, over the study period of 30 days 
after activation  of study drug.  
Secondary Efficacy Endpoint:  
• Number of platelet transfusions per patient during the first 30 days post activation of study drug  
• Number of days alive and without WHO grade 2 bleeding or greater during the first 30 days 
after activation  of study drug  
Supportive and Exploratory Efficacy Endpoints:  
Alternative measures of bleeding  
• Number of days with bleeding/thrombocytopenia during th e first 30 days post activation  of 
study drug  
• Time from activation  of study drug to first episode of bleeding of WHO grade 2 or greater or 
death, whichever comes first  within the first 30 days post activation of study drug  
• Highest grade of bleeding a patie nt experiences during the first 30 days post activation  of study 
drug 
• Death ascribed to bleeding during the first 30 days post activation  of study drug  
        
Alternative measures of transfusion frequency  
• Number of platelet transfusions/patient by thrombocytopenic day during the first 30 days post 
activation  of study drug  
• Number of red cell transfusions/patient and by thrombocytopenic day during the first 30 days 
post activation  of study drug  
• Proportion of patients surviving at least 30 days post activation  of study drug without a platelet 
transfusion  
• Proportion of patients surviving at least 30 days post activation  of study drug without a red cell 
transfusion  
• Number of patients with platelet count nadir > 10,000/l over the study period of 30 days from 
activation  of study drug  
Safety Endpoints:  
• Incidence of thrombotic events from first day on study drug up to and including 120 days  after 
activation  of study drug . 
• Incidence of veno -occlusive Disease (VOD; sinusoidal obstructive syndrome, SOS) from the 
first day on study drug up to and including 30 days of last receipt of study drug  
• All-cause mortality during the first 30 days and the first 120 days post activation  of study drug  
• Death ascribed to throm bosis during the first 120 days post a ctivation  of study drug  
Page 12 of 63 
 • Incidence of adverse events (AEs) and serious adverse events (SAEs) categorized by CTCAE 
v4.0 from the first day on study drug up to and including 30 days after the last dose of study 
drug is re ceived  
Sub-Group Analysis:  
• WHO grade 2 or above bleeding will be assessed separately among patients who did and did 
not have bleeding at randomization , as well as within each of the disease groups of allogeneic 
transplant, autologous transplant, and leukem ia. 
 
Statistical Methods and Sample Size:  
The odds of bleeding at WHO grade 2 level or above will be analyzed in a logistic regression model 
adjusting for treatment arm ,  clinical site as a factored variable , and disease group (a llogeneic 
transplant, autologous transplant, or leukemia ) as a factored variable . The test statistic will be based on 
the score statistic for the treatment arm parameter from the logistic regression model with adjustment 
for multiply imputed missing data.  
 
Calculation of sample size and statistical power were based on the chi -squared test of association, 
which is equivalent to the score test from simple logistic regression. Based on 1:1 randomization, a 
one-sided level of significance 0.025, a design alter native hypothesis of 30% relative reduction in 
bleeding rates (57% on the placebo arm and 40% on TXA), a sample size of 330 subjects (165 TXA, 
165 placebo) will provide 88% statistical power to declare statistical significance on the primary 
endpoint. This  sample size will provide 74.8% statistical power to detect a 25% relative reduction in 
bleeding rates (57% vs 42.75%). With the planned sample size and a placebo bleeding rate of 57%, an 
observed absolute decrease in WHO grade 2 or above bleeding of 10.6%  (so 57% on placebo, 46.4% 
on TXA) would be judged statistically significant.   
 
 
 
  
Page 13 of 63 
   
2. BACKGROUND  
Despite major advances in optimizing platelet transfusion therapy, bleeding remains a problem 
in patients with thrombocytopenia due to chemotherapy induced marrow aplasia and primary 
hematopoietic stem cell disorders1.  Baseline level of bleeding does not appear to be affected 
by increasing the platelet transfusion threshold2,3, and does not appear to be dependent on 
the platelet count when it is above 5,000/ l.  In the P LADO (Platelet Dose) Trial of 1272 
patients, WHO grade 2 bleeding occurred in approximately 70% of all subjects regardless of 
platelet dose transfused prophylactically for patients with platelet counts of ≤10,000/µL4. 
Similarly in a 600 patient trial of therapeutic vs. prophylactic platelet transfusion (TOPPS)6, 

Page 14 of 63 
 bleeding remained a common event. Withholding transfusion may lead to serious and fatal 
bleeding5.  
 
Maintenance of the platelet count in a safe range may be difficult due to severe shortening of 
the platelet survival in severely thrombocytopenic and critically ill patients7 and patients who 
are refractory to platelet transfusion therapy may require specially matched platelets that are 
difficult and expensive to obtain. In the outpatient setting, maintenance of the platelet coun t 
above a prescribed trigger may require almost daily laboratory work and frequent transfusions.  
 
Platelet transfusions are a limited and expensive resource, and demand for these products is 
rising in many countries. The increasing demand for platelet transfusions in the US r aises 
concerns  of future shortages . Hematology/Oncology patients are transfused more platelets 
than any other hospital service (31%)13. Any treatment that could reduce reliance on platelet 
transfusion support would have major cost -saving implications.  
 
Other means that have been used to decrease bleeding incidence include maintenance of 
higher hematocrits to improve platelet function14 and the use of pharmacologic agents to 
improve platelet function15,16. Epsilon Aminocaproic Acid (EACA) and Tranexamic Acid (TXA) 
are inhibitors of fibrinolysis that can be given either intravenously or orally. Inhibitors of 
fibrinolysis have been used for  many years to prevent and treat bleeding due to fibrinolysis 
intra- and postoperatively8. These drugs have also been shown to be useful in patients with 
platelet function and coagulation defects such as hemophilia17. Reports of the use of these 
agents to prevent or treat bleeding in thrombocytopenic patients have been 
encouraging9,10,11,12  and suggest that in many patients bleeding can be prevented or stopped 
with the use of these a gents. However, the reports of success have been anecdotal and 
retrospective reviews of single institution experiences. Currently many physicians administer 
antifibrinolytic agents to treat bleeding in thrombocytopenic patients or to prevent bleeding in 
the thrombocytopenic patient refractory to platelet transfusions.  Due to the lack of evidence of 
its efficacy and safety, the treatment has not become standard of care. A pivotal study of 
antifibrinolytic therapy will improve patient care by leading physici ans to either adopt it as an 
effective and safe treatment for the prevention of thrombocytopenic bleeding, or to abandon i ts 
use for this purpose.  
 
The purpose of this study is to conduct a prospective, randomized, blinded, placebo controlled 
trial to eva luate the usefulness of an antifibrinolytic therapy, TXA, in preventing bleeding in 
patients who are thrombocytopenic due to primary bone marrow disorders or chemotherapy, 
immunotherapy and/or radiation therapy. The results of this study will change practice by 
providing evidence as to whether or not TXA is an effective and safe treatment when used as 
an adjunct to platelet transfusion therapy in the thrombocytopenic patient.  
 
3. ENDPOINTS  
3.1 PRIMARY ENDPOINT  
Proportion of patients with bleeding of WHO grade 2 or above during the first 30 days after 
activation  of study drug  (appendix 2) . 
 
3.2 Secondary Endpoint s 
• Number of platelet transfusions per patient during the first 30 days post activation  of 
study drug  
• Number of days alive and without WHO grade 2 bleeding or greater during the first 30 
days post activation  of study drug  
 
3.3 Supportive and Exploratory Efficacy Endpoints  
3.3.1  Alternative measures of bleeding:  
• Number of days with bleeding/thrombocytopenia during th e first 30 days post 
activation  of study drug  
Page 15 of 63 
 • Time from activation  of study drug to first episode of bleeding of WHO grade 2 
or greater or death, whichever comes first  
• Highest grade of bleeding a patient experiences during the first 30 days post 
activation  of study drug  
• Death ascribed to bleeding during the first 30 days post activation  of study drug  
3.3.2  Alternative Measure of Transfusion Frequency:  
• Number of platelet transfusions/patient by thrombocytopenic day during the first 
30 days post activation  of study drug . 
• Number of red cell transfusions/patient and by thrombocytopenic day during the 
first 30 days post activation  of study drug . 
• Proportion o f patients surviving at least 30 days post activation  of study drug  
without a platelet transfusion.  
• Proportion of patients surviving at least 30 days post activation  of study drug 
without a red cell transfusion . 
• Number of patie nts with platelet count nadir  > 10,000 /l over the study period of 
30 days from activation  of study dru g. 
 
3.4 Safety Endpoints  
The incidence of serious adverse events (SAEs) and adverse events (AEs) will be collected 
from the time of consent, up to and including 30 days after the last dose of study drug, 
categorized using CTCAE v4.0 criteria, and compared across treatment arms. In addition, the 
following protocol defined safety endpoints will be collected:  
• Incidence of thrombotic events from first day on study drug up to and including 120 
days  after activation of study drug .  Thrombotic event is defined by the presence of a 
venous or arterial clot demonstrated by positive diagnostic imaging, which can include 
Doppler/ultrasound, CT and MRI, and interpretation by a local radiologist who will be 
blinded to the study assignment and unlikely to know patient is on a study. Acute 
coronary  syndrome will be made on the basis of enzyme and EKG abnormalities 
consistent with that diagnosis and interpreted by the attending physician or consulting 
cardiologist as such.  
• Incidence of veno -occlusive Disease (VOD; sinusoidal obstructive syndrome, SOS ) 
from the first day on study drug up to and including 30 days after last dose  of study 
drug. 
• All-cause mortality during the first 30 days and the first 120 days post activation  of 
study drug . 
• Death ascribed to thrombosis during the first 120 days post activation  of study drug . 
 
3.5 Sub-group Analyses  
WHO grade 2 or above bleeding will be assessed separately among patients who did and did 
not have bleeding at randomization , as well as within each of the disease groups of allogeneic 
transplant, autologous transplant and leukemia . 
 
4. TARGET PATIENT POPULATIONS  
Patients with hematologic malignancies receiving intensive chemotherapy and/ or stem cell 
transplantation.   
4.1 Inclusion Criteria  (all must be met)  
4.1.1  ≥18 years of age  
4.1.2  Confirmed diagnosis of a hematological malignancy  or aplasia  
4.1.3  Undergoing or planned chemotherapy , immunotherapy,  or hematopoietic stem 
cell transplantation  
4.1.4  Anticipated to have hypoproliferative thrombocytopenia resulting in a platelet           
count of ≤  10,000 /l for ≥ 5 days  
4.1.5  Able to provide informed consent and comply with treatment and monitoring  or 
having a Legally Authorized Representative (LAR)  
 
Page 16 of 63 
 4.2 Exclusion Criteria  (none can be present)  
4.2.1  Diagnosis of acute promyelocytic leukemia undergoing induction chemotherapy  
4.2.2  History of ITP, TTP or HUS  
4.2.3  Subjects receiving L -asparaginase as part of their current cycle of treatment  
4.2.4  Subjects with a past history or current diagnosis of arterial or venous     
thromboembolic disease including, acute coronary syndrome peripheral vascular 
disease and retinal arterial or venous thrombosis  (except when a prior history of 
central line thrombosis has resolved)  
4.2.5  Subjects with a diagnosis/previous history of veno -occlusive disease (also  
called sinusoidal obstruction syndrome)  
4.2.6  Subjects receiving any pro -coagulant agents (e.g. DDAVP, recombinant Factor    
 VIIa or Prothrombin Complex Concentrates (PCC) ) and/or an an tifibrinolytic      
 agent within 48 hours of enrollment, or with known hypercoagulable state  
4.2.7  Known inherited or acquired bleeding disorder (e.g. Acquired Storage Pool    
 Deficiency, Paraproteinemia with Platelet Inhibition)  
4.2.8  Known inherited or acquired prothrombotic disorders , including 
antiphospholipid syndrome.  Those with lupus anticoagulant or positive 
antiphospholipid serology without thrombosis are not excluded  
4.2.9  Subjects receiving anticoagulant therapy or anti -platelet therapy  
(except   when   receiving prophylactic anticoagulant or low dose aspirin therapy for 
prophylaxis only with a plan to discontinue when the platelet count falls below 
50,000)  
4.2.10  Subjects  with DIC (per diagnosis of  patient’s provider ) 
4.2.11  Subjects with WHO Grade 2 bleeding  or greater within 48 hours prior to  
activation  
4.2.12  Subjects requiring a platelet transfusion threshold > 10 ,000 /l at time of  
 randomization  
4.2.13  Subjects with anuria (defined as urine output < 10 mls/hr over 24 hours)   
4.2.14  Subjects on dialysis  
4.2.15  Subjects with creatinine ≥ 5.7 mg/dL  
4.2.16  Subjects who are pregnant  or nursing  or unwilling to use contraception during 
and for 30 days after taking the study drug   (both males and females)  
4.2.17  Concurrent enrollment in other trials involv ing platelet transfusions, anti 
 fibrinolytics, platelet growth factors or other pro -coagulant agents  
4.2.18  Known allergy to tranexamic acid 
4.2.19  Having been previously randomized in to the A-TREAT  study at any stage of  
 their treatment  
4.2.20  Subjects who are unwilling to accept blood or blood component transfusions  
 
5. TRIAL ENROLLMENT  
5.1 Screening/Recruitment  
5.1.1  Potentially eligible subjects  will be identified by the subject’s physician and/or 
by other IRB approved methods at each trial site. Rese arch staff will commence 
screening to determine if the subject is eligible for enrollment based upon their 
medical history and laboratory results. The eligibility checklist will be completed.   
Each site will maintain a local log for all screened patients w hich will contain the 
case ID (assigned by DCC), site linking ID (assigned by site), and identifiable PHI 
in accordance with their local IRB regulations in order to correctly identify each 
patient.  This will be done in order to prevent duplicate screening .  The site staff will 
enter screening information via secure web -based data entry only using the case 
ID and site linking ID.   
5.1.2  After obtaining permission from the subjects physician to discuss  the study with 
the subject a trained research staff member will contact the prospective subject to 
describe the study and obtain consent.  
5.1.3  After signing the consent form the subject will be entered into the study .   
 
5.2 Stratification and Randomization  
Page 17 of 63 
 5.2.1  The subjects will be stratified according to clinical site and disease group 
(allogeneic transplant, autologous transplant, or leukemia) and will be balanced 
within varying blocks of undisclosed sizes.  
5.2.2  When the consented patient’s platelet co unt falls to < 50 ,000/l with an 
expectation that the platelet count will be ≤10,000 for 5 days, the PI or a research 
staff member will access the on -line randomization system and a unique trial 
number will be assigned.  
5.2.3  A member of the study team will contact the local investigational pharmacy to 
inform them of the patient’s participation in the trial and study ID number.  
5.2.4  When a randomized subject has a platelet count < 30 ,000 /l with an 
expectation that the platelet coun t would be ≤10,000 /l for 5 days, the 
administration of study drug will be activated, providing the date of activation is 
within 30 days of randomization. The date/time of activation will be time zero for 
the study endpoints.  
5.2.5  Target enrollment will be 330 activated subjects - utilizing a 1:1 randomization 
schema both arms will have a target enrollment of 165 activated subjects.  
 
5.3 Enrollment Period  
Trial enrollment will take place over a period of 4 years. The expected enrollment is estimated 
to be 90 randomiz ed subjects per year , with 82 activated subjects per year,  across all sites.  
 
6. INTERVENTIONS  
6.1 Study Drug  (Tranexamic Acid or placebo)  
6.1.1  Tranexamic acid is a competitive inhibitor of plasminogen activation and, at much 
higher concentrations, acts as a noncompetitive inhibitor of plasmin and 
fibrinolysis.   Patients randomized to receive TXA will take 1 .3g PO (by mouth)   
three times a day until they meet the criteria for stopping study drug as provided 
in section 6.3.  
6.1.1a  Any patients unable to take the drug orally will receive 1.0g TXA IV 
(intravenous ) three times a day . 
6.1.1b  Criteria for dose reduction in the presence o f renal insufficiency are given 
for both PO and IV administration in section 6. 5 
6.1.1c  Criteria for temporary discontinuation of the study drug are given in section 
6.4. 
      6.1.2  Patients randomized to the control arm will receive matching placebo ( tablets  or 
IV solution as described in section 7.1 ) 
      6.1.3  Rationale for dose:   The experimental doses have been chosen to be in line with    
           the current approved indications of TXA and to be in the midrange of the doses that    
           have been previously studied in patient populations similar to those to  be accrued  
           to this study.  
      6.1.4  The current indications for oral TXA (L YSTEDA) are for heavy menstrual  
           bleeding at a dose of 1 .3g t.i.d (three times daily) (total 3 .9g/day) for a maximum of  
           5 days, with reduced d osage in patients with renal impairment . The current  
      indication for intravenous TXA (CYKL OKAPRON) is in patients with hemophilia for  
           short -term use (two  to eight days) to reduce or prevent hemorrhage and reduce the  
      need for replacement therapy during and following tooth extraction . Dosage is  
      0.01g/kg body weight three to four times per  day for 2 – 8 days after tooth  
           extraction. Dos age is to be modified in patients with renal impairment .  
      6.1.5 Append ix 1 contains a listing of prior studies of anti -fibrinolytics TXA (Tables 1  
            and 2) and EACA (Tables 3 and 4) in patients s imilar to the populations to be  
       enroll ed in this study. Table 5 of Appendix 1 contains a listing of prior studies that  
            compared TXA to EACA in any indication.  
 
6.2 Transfusion Practice  on both arms  
      6.2.1  Prophylactic platelet transfusions will be given when the morning  platelet count is              
           ≤ 10,000 /l  
Page 18 of 63 
       6.2.2  Therapeutic platelet transfusions may be given fo r active bleeding , prior to  a    
            planned  invasive procedure or because of trauma , per local standard of care .  
      6.2.3  In instances where  platelet transfusions are g iven for invasive procedures or  
            trauma, the subject will return to the study platelet transfusion threshold of  
      ≤ 10,000 /l  
      6.2.4  Type and dose of platelet transfusion will not be specified.  
      6.2.5  Clinicians can exercise discretion to transfuse platelets for any reason should  
           they feel there is a clinical reason to do so  (e.g. patient’s platelet count appears to  
           be falling just prior to a weekend).   
      6.2.6  If a patient develops platelet transfusion refractori ness (defined as two sequential  
           transfusions with a 24 hour platelet increment < 5 ,000 /l), local practices for      
      transfusion management will be followed . Data on use of matched platelets and 
     alloantibody testing will be recorded . 
      6.2.7  The rationale for platelet transfusion over 10 ,000 /l will be recorded on the daily  
           transfusion data form.  
      6.2.8  Patients will receive a transfusion of red blood cells per standard of care at their  
           clinical site.  
 
6.3  Stopping of Study Drug  
Study drug will be permanently discontinued  as soon as any one of the following situation s 
occurs:  
6.3.1  It has been 30 days since the subject was first activated to the randomized study 
drug.  
6.3.2  The subject has a spontaneous increase in platelet count across 2 successive 
platelet measurements made at least 22 hours apart from <30,000 /l to >50,000 /l, 
with no intervening  platelet or granulocyte transfusion, or stem cell transplant.    
6.3.3  If plat elet counts are ≥30,000 on 2 measurements made at least 46 hours apart 
with no intervening platelet counts <30,000, with no greater than a 25% decrease 
in platelet counts from the first such measurement to a follow -on measurement 
during that 46 hour period, and with no intervening platelet or granulocyte 
transfusion, or stem cell transplant.  
6.3.4 The subject receives open label TXA, or other a ntifibrinolytic agent or  
      procoagulant drug, (e.g., EACA, DDAVP, recombinant Factor VIIa, or Prothrombin  
      Complex Concentrates). Use of these agents will be recorded in study data.  
6.3.5 The subject begins anticoagulant or antiplatelet therapy.  
6.3.6 The subject has visible hematuria.  
6.3.7 The subject has a diagnosis of thrombosis.  
6.3.8 The subject develops sinusoidal obstructive s yndrome (SOS), also called Veno  
      occlusive Disease (VOD).  
6.3.9 A recurrent inciden t of central line occlusion .  Central line occlusion is defined as 
inability to access or infuse through a central line requiring instillation of a fibrinolytic 
agent  such as urokinase for clearing. It will not require radiographic or 
ultrasonographic evidence for diagnosis. It does  not include lines that requ ire specific 
patient positioning that suggests a “kink” in the line.   A recurrent incident is when the 
definition is met on 2 separate occasions while receiving study drug.  
6.3.10 The subject becomes pregnant.  
 
If the study drug is stopped for any of the a bove reasons, it should not be restarted even if the 
platelet count later falls below 30,000.  
 
6.4 Temporary  Discontinuation of Study Drug  
Study drug will be temporarily discontinued and may be restarted after resolution for the 
following situations:  
6.4.1  A diagnosis of DIC is made by the clinical team.  
6.4.2  Central line occlusion occurs (drug must be permanently discontinued if central  
      line occlusion recurs) . 
Page 19 of 63 
  
6.5 Dose Adjustment for Renal Insufficiency  
Study drug d osing frequency will be adjusted for renal insufficiency  according to the following 
algorithm  (dose adjustments will be based upon the first creatinine measurement on any given 
day): 
Serum Creatinine (mg/dL)  Dosing Frequency  
1.36 to 2.82  Once every 12 hours  
2.83 to 5.66  Once every 24 hours  
>5.66  Once every 48 hours  
 
Patients who must begin dialysis  after beginning study drug  will continue to receive study drug 
once every 48 hours.  
 
6.6 Other Treatment Considerations  
No other medication changes  are directed in this protocol and standard care will otherwise be 
followed . 
 
7. STUDY DRUG INFORMATION  
7.1 Masking of Study Drug  (Tranexamic Acid or placebo)  
7.1.1  Inpatient Subjects  
• The investigational pharmacy at each trial site will receive randomization 
and distri bute TXA or placebo  (both IV and PO) . The manufacturer of the 
oral drug commercially known as LYSTEDA ® is Apotex Corporation and the 
NDC# is 60505 -3638 -01.  The manufacturer of the IV drug commercially 
known as CYKLOKAPRON ® is Pfizer Corporation and the NDC# is NDC 
0013 -1114 -10. IV diluent and IV placebo may be 0.9% sodium chloride or 
D5W.  
• A central drug distribution center , CoreRx , will prepare and package oral 
tranexamic acid and placebo , and then distribute blinded containers to the 
investigational pharmacy at each participating trial site. Containers will be 
coded for TXA arm vs placebo arm.  
• For patients who cannot tolerate or absorb oral medication  (per the 
discretion of the treating investigator  or physician ), the investigational 
pharmacy at each trial site will distribute TXA or placebo as equal volumes 
of TXA in solution or solution alone. The manufacturers, batch numbers, 
and sources will be reported for all doses. Sites will use the commercia lly 
available product used by their formulary.  
• Although the investigational pharmacy will be unblinded, they will not share 
any blinded information with the study team except in case of emergency.   
Unblinded pharmacy staff will not be involved in patient o r outcomes 
assessment.  
7.1.2  Outpatient Subjects  
• CoreRx  will prepare, package and  distribute blinded containers of oral study 
drug to the investigational pharmacy at each participating trial site. Vials will 
be coded for TXA arm vs placebo arm.  
7.1.3  Blinding of patie nts, caregivers, and study personnel  
• Double blind randomization: Neither patients nor care providers nor study 
coordinators nor study investigators will be told which arm the patient is on.  
• Among study personnel, only the unblinded pharmacists and unblinded 
statistician will have access to treatment assignment.  
• Placebo is manufactured to be grossly similar to TXA in appearance (size, 
shape, color).  
Page 20 of 63 
 • To mitigate the possibility of bias in assessing treatment outcomes, 
research coordinators who collect  outcomes data will have no contact with 
study drug. Details about the measures instituted to preserve assessor 
blind will be described in the Manual of Operations.  
 
7.2 Administration of Study Drug  
7.2.1  Study drug will be started per randomization assignment withi n 24 hours of the 
first recorded platelet count < 30,000 /l. 
7.2.2  Dose Schedule  
• Intravenous Administration: tranexamic a cid 1 g  (diluted to 50 mL)  every 8 
hours or placebo (50 mL) every 8 hours ; both TXA and placebo will be 
infused over 15 to 30 minutes , then the line is flushed with 25ml saline  or 
according to institutional standard practice . 
• Oral Administration: tranexamic a cid 1.3 g every 8 hours or  an identical, 
inert placebo capsule  
7.2.3  TXA for Intravenous Administration  
• Tranexamic a cid may be mixed with most solutions (e.g.  electrolyte 
solutions, carbohydrate solutions, amino acid solutions  and Dextran 
solutions ). 
• Tranexamic acid should  not be mixed with blood  products .  
• The mixture should be prepared the same day the solution is to be used.  
• Each mL of the sterile solution for intravenous injection contains 100 mg 
tranexamic  acid and w ater for Injection to 1 mL.   
• Intravenous TXA will be diluted to a 50 mL solution that will be infused over 
15 to 30 minutes , and then the line is flushed with 25 ml saline  or 
according to institutional standard practice . 
7.2.4  TXA for Oral Administration  
• Each tablet of TXA (non-placebo) contains  650 mg tranexamic  acid and the 
following inactive ingredients:  microcrystalline cellulose, colloidal silicon 
dioxide, pregelatinized corn starch, povidone, hypromellose, stearic acid, 
and magnesium stearate.   
7.2.5  Placebo for Oral Administration  
• CoreRx  will manufacture the placebo  to be similar in size, shape, and color 
to the TXA tablet .  
• The placebo tablets will be 650 mg microcrystalline cellulose (MCC)  since 
there would be a risk of developing lactose intolerance in this population 
with the commonly used lactose filler .  This avoids adding additional 
ingredients over the TXA.  In addition to MCC, the placebo will contain 
magnesium stearate  (0.5% or ~5mg/tablet) which is added as a lubricant 
for the manufacturing process.  
 
8. STUDY VISIT PROCEDURES AND SCHEDULE  
The following da ta will be collected as specified.  
 
If two or more of the following study time -points fall on the same calendar date, all data 
required at each time -point must be collected. However, corresponding measurements that 
occur on both time -points do not need to be repeated. For example, if a subject receives study 
drug (D1 of treatment) on the same day as enrollment & randomization - all measurements to 
be collected on Day of Enrollment and Day of Randomization and D1 of Active Treatment 
must be done that day, but  only one platelet count (or hemoglobin level, hematocrit level, etc.) 
is required.  
 
8.1 Day of Enrollment   
• Thrombotic Assessment  
• Demographics and Medical History  
Page 21 of 63 
 o Weight  
o Height  
o Date of Birth  
o Gender  
o Ethnicity  
o Race  
o Primary Diagnosis  
▪ Disease  
▪ Current Treatment  
o Chemotherapy?  
o Transplant? If yes, date and type.  
▪ If receiving allogeneic transplant : 
o Donor ABO Type  
o Related Donor?  
o Subject ABO Type  
• Laboratory Assessments  
o Hematocrit  
o Hemoglobin  
o Platelet Count  
o WBC  
o Neutrophil (if available)  
o Serum Creatinine  
o Pregnancy Test  (if not done within prior 7 days)  
▪ Only Females of Childbearing Potential (FCBP)  
▪ Urine or Serum (qualitative or quantitative) pregnancy test 
acceptable  
o Results of  HLA antibody testing  done as routine care will be recorded  
 
• Adverse Event Assessment and Reporting - adverse events are monitored from time 
of consent to 30 days post discontinuation of study drug.  
 
8.2 Days Between Enrollment and Randomization  
• Thrombotic Assessment (via chart review) - to be performed once a week  
• Laboratory Assessments  
INPATIENT SUBJECTS: to be performed daily  
OUTPATIENT SUBJECTS:  to be performed twice a week  
o Hematocrit  
o Hemoglobin  
o Platelet Count  
o WBC  
o Neutrophil (if available)  
 
• Adverse Event Assessment and Reporting  
 
8.3 Day of Randomization  
• Hemostatic/Bleeding Assessment  
o If WHO Grade 2 bleeding or greater at randomization or within prior  48 
hours, do not randomize. They are eligible for randomization if bleeding 
resolves later.  
Page 22 of 63 
 • Thrombotic Assessment (via chart review)  
• Laboratory Assessments  
o Hematocrit  
o Hemoglobin  
o Platelet Count   
o WBC  
o Neutrophil (if available)  
o Coagulation Profile (PT/INR, aP TT, Fibrinogen, D -dimer) :must be drawn 
no longer than 24 hours before randomization or 24 hours after 
randomization and reviewed prior to activation  
o Serum Creatinine  
o Urinalysis  
o Pregnancy Test if > 7 days since last pregnancy test  
▪ Only Females of Childbearing Potential (FCBP)  
▪ Urine or Serum (qualitative or quantitative) pregnancy test 
acceptable  
• Data on Platelet and Granulocyte Transfusions  
o Source of Platelets (apheresis or whole blood derived)  
o HLA or cross -match compatible  
o Reason for Transfusion  
▪ Met Threshold  
▪ Invasive Procedure  
▪ Active Bleeding  
▪ Risk of Significant Bleeding  
▪     Other - specify  
• Data on RBC Transfusions  
o Number of Units Transfused  
o Reason for Transfusion   
▪ Met Threshold  
▪ Invasive Procedure  
▪ Active Bleeding  
▪ Risk of Significant Bleeding  
▪ Other - specify  
• Adverse Event Assessment and Reporting  
 
8.4 Days Between Randomization and Activation  
• Hemostatic/Bleeding Assessment  
• Thrombotic Assessment (via chart review)  weekly  
• Laboratory Assessments:  
INPATIENT SUBJECTS: to be performed daily  
OUTPATIENT SUBJECTS:  to be performed twice a week  
o Hematocrit  
o Hemoglobin  
o Platelet Count  
o Serum Creatinine  
o WBC  
o Neutrophil (if available)  
• Data on Platelet and Granulocyte Transfusions  
o Source of Platelets (apheresis or whole blood derived)  
Page 23 of 63 
 o HLA or cross -match co mpatible  
o Reason for Transfusion  
▪ Met Threshold  
▪ Invasive Procedure  
▪ Active Bleeding  
▪ Risk of Significant Bleeding  
▪ Other - specify  
• Data on RBC Transfusions  
o Number of Units Transfused  
o Reason for Transfusion  
▪ Met Threshold  
▪ Invasive Procedure  
▪ Active Bleeding  
▪ Risk of Significant Bleeding  
▪ Other - specify  
• OUTPATIENT SUBJECTS ONLY : Subject Self -Assessment Bleeding Diary - provide 
patients with instruction on how to complete diary. This diary will be reviewed with 
research staff (in person or by phone) at least once a week.  
• Adverse Event Assessment and Reporting  
 
8.5 Activation  
• Days Between Activation and First Dose of Study Drug  
o Hemostatic/Bleeding Assessment  – daily while inpatient  
▪ If WHO Grade 2 bleeding or greater within prior 48 hours, do NOT 
activate -not eligible.  
o Thrombotic Assessment (via chart review)  weekly  
o Laboratory Assessments:  
▪ Hematocrit  
▪ Hemoglobin  
▪ Platelet Count  
▪ Serum Creatinine  
▪ WBC  
▪ Neutrophil (if available)  
▪ Bilirubin (if not done within 7 days prior)  
o Check to see if bilirubin is ordered weekly  while on study 
drug-all subjects and order if not otherwise clinically 
indicated  
o Data on Platelet and Granulocyte Transfusions  
▪ Source of Platelets (apheresis or whole b lood derived)  
▪ HLA or cross -match compatible  
▪ Reason for Transfusion  
o Met Threshold  
o Invasive Procedure  
o Active Bleeding  
o Risk of Significant Bleeding  
o Other - specify  
o Data on RBC Transfusions  
▪ Number of Units Transfused  
▪ Reason for Transfusion  
Page 24 of 63 
 o Met Threshold  
o Invasive Procedure  
o Active Bleeding  
o Risk of Significant Bleeding  
o Other - specify  
o Study Drug Administration  
o OUTPATIENT SUBJECTS ONLY : Subject Self -Assessment Bleeding 
Diary - provide patients with instruction on how to complete diary. This 
diary will  be reviewed with research staff (in person or by phone) at least 
once a week.  
o Adverse Event Assessment and Reporting  
• Day 1 of Study Drug  
o Hemostatic/Bleeding Assessment  
o Thrombotic Assessment (via chart review)  
o Ocular Assessment  
Day of first dose up to no more than 72 hours before  
o Laboratory Assessments:  
Day 1 labs MUST  be drawn BEFORE  the first dose of study drug is 
administered  
▪ Hematocrit  
▪ Hemoglobin  
▪ Platelet Count  
▪ Serum Creatinine  
▪ WBC  
▪ Neutrophil (if available)  
o Data on Pla telet and Granulocyte Transfusions  
▪ Source of Platelets (apheresis or whole blood derived)  
▪ HLA or cross -match compatible  
▪ Reason for Transfusion  
o Met Threshold  
o Invasive Procedure  
o Active Bleeding  
o Risk of Significant Bleeding  
o Other - specify  
o Data on RBC Transfusions  
▪ Number of Units T ransfused  
▪ Reason for Transfusion  
o Met Threshold  
o Invasive Procedure  
o Active Bleeding  
o Risk of Significant Bleeding  
o Other - specify  
o Study Drug Administration  
o OUTPATIENT SUBJECTS ONLY : Subject Self -Assessment Bleeding 
Diary - provide patients with instruction on how to complete diary. This 
diary will be reviewed with research staff (in person or by phone) at least 
once a week.  
o Adverse Event Assessment and Reporting  
 
Page 25 of 63 
 • Day 2 of Study Drug  
o Hemostatic/Bleeding Assessment  
o Thrombotic Assessment (via chart review)  
o Laboratory Assessments  
   INPATIENT SUBJECTS: to be performed daily  
   OUTPATIENT SUBJECTS:  to be performed twice a week  
▪ Hematocrit  
▪ Hemoglobin  
▪ Platelet Count  
▪ WBC  
▪ Neutrophil (if available)  
▪ Serum Creatinine  
o Data on Platelet and Granulocyte Transfusions  
▪ Source of Platelets (apheresis or whole blood derived)  
▪ HLA or cross -match compatible  
▪ Reason for Transfusion  
o Met Threshold  
o Invasive Procedure  
o Active Bleeding  
o Risk of Significant Bleeding  
o Other - specify  
o Data on RBC Transfusions  
▪ Number of Units T ransfused  
▪ Reason for Trans fusion  
o Met Threshold  
o Invasive Procedure  
o Active Bleeding  
o Risk of Significant Bleeding  
o Other - specify  
o Study Drug Administration  
o OUTPATIENT SUBJECTS ONLY : Subject Self -Assessment Bleeding 
Diary - ensure patients are filling out diary correctly  (in person or by 
phone) . 
o Adverse Event Assessment and Reporting  
 
• Day 3 – 30 of Study Drug  or up to day 30 post activation  
o Inpatient Subjects  
▪ The following are to be performed daily:  
o Hemostatic/Bleeding Assessment  
o Thrombotic Assessment (via chart review)  
o Laboratory Assessments  
❖ Hematocrit  
❖ Hemoglobin  
❖ Platelet Count  
❖ WBC  
❖ Neutrophil (if available)  
❖ Serum Creatinine  
Page 26 of 63 
 ❖ Check to see if bilirubin is  ordered weekly  while 
on study drug -all subjects and order if not 
otherwise clinically indicated  
o Data on Platelet and Granulocyte Transfusions  
❖ Source of Platelets (apheresis or whole blood 
derived)  
❖ HLA or cross -match compatible  
❖ Reason for Transfusion  
1. Met Threshold  
2. Invasive Procedure  
3. Active Bleeding  
4. Risk of Significant Bleeding  
5. Other - specify  
o Data on RBC Trans fusions  
❖ Met Threshold  
❖ Invasive Procedure  
❖ Active Bleeding  
❖ Risk of Significant Bleeding  
❖ Other - specify  
o Study Drug Administration  
o Adverse Event Assessment and Reporting  
▪ The following are to be performed weekly:  
o Ocular Assessment -additionally if symptoms reported  
o Outpatient Subjects  
▪ The following are to be performed daily:  
o Study Drug Administration  
o Self-bleeding assessment and recorded in diary  
▪ The following are to be performed twice a week:  
o Hemostatic/Bleeding Assessment  
o Thrombotic Assessment (vi a chart review)  
o Laboratory Assessments  
❖ Hematocrit  
❖ Hemoglobin  
❖ Platelet Count  
❖ WBC  
❖ Neutrophil (if available)  
❖ Serum Creatinine  
❖ Check to see if bilirubin is ordered weekly  while 
on study drug -all subjects and order if not 
otherwise clinically indicated  
 
o Data on Platelet and Granulocyte Transfusions  
❖ Source of Platelets (apheresis or whole blood 
derived)  
❖ HLA or cross -match compatible  
❖ Reason for Transfusion  
1. Met Threshold  
2. Invasive Procedure  
3. Active Bleeding  
Page 27 of 63 
 4. Risk of Significant Bleeding  
5. Other - specify  
o Data on R BC Transfusions  
❖ Number of Units Transfused  
❖ Reason for Transfusion  
1. Met Threshold  
2. Invasive Procedure  
3. Active Bleeding  
4. Risk of Significant Bleeding  
5. Other - specify  
▪ The following are to be performed once a week:  
o Ocular Assessments -additionally if symptoms report ed 
o Subject Self -Assessment Bleeding Diary review with 
research staff (in person or by phone)  
• At Onset of ≥ Grade 2 Bleeding:  to be performed on day of onset of symptoms or at 
visit directly following onset of symptoms.   
o Laboratory Assessments  
▪ Hematocrit  
▪ Platelet Count  
▪ Hemoglobin  
▪ WBC  
▪ Neutrophil (if available)  
▪ Coagulation Profile  (PT, aPTT, INR, Fibrinogen, D -dimer)  (if 
available)  
▪ Serum Creatinine  
 
8.6 End of Treatment:  the day the subject receives their last dose of study drug OR at the 
next visit following last dose of study drug.  
• Hemostatic/Bleeding Assessment  
• Thrombotic Assessment (via chart review)  
• Laboratory Assess ments  
o Hematocrit  
o Hemoglobin  
o Platelet Count  
o WBC  
o Neutrophil (if available)  
o Serum Creatinine  
• OUTPATIENT SUBJECTS ONLY : Subject Self -Assessment Bleeding Diary - to be 
reviewed with research staff (in person or by phone) at end of treatment.  
• Adverse Event Assessment and Reporting  
 
8.7 End of Treatment to Day 14 post Discontinuation of Study Drug  (Safety Phase)  
• Inpatient Subjects  
o Hemostatic/Bleeding Assessment and Thrombotic Assessment (via chart 
review)  will occur daily  
o Adverse Event Assessment and Reporting  
o Weekly ocular assessments -additionally if symptoms reported  
• Outpatient Subjects  
Page 28 of 63 
 o Outpatient subjects will complete the daily Follow -Up Subject Self -
Assessment Bleeding Diary  (and any necessary Self -Assessment 
Bleeding Forms) which will be reviewed with the research staff (in person 
or by phone) at least weekly  
o Adverse Event Assessment and Reporting  
o Weekly ocular assessments -additionally if symptoms reported  
 
8.8 Follow Up  
• +30 Days (-1 + 6 days) post Discontinuation of Study Drug  (Safety Phase)  
o Patient will be co ntacted in person or by telephone (see telephone script - 
Appendix  3) 
o OUTPATIENT SUBJECTS ONLY : a final review (in person or by phone) 
of the Follow -Up Self -Assessment Bleeding Diary (and any necessary 
Self-Assessment Bleeding Forms) will be conducted and diaries and 
forms will be returned to the study team  
o Thrombotic Assessment (via chart review)  
o Adverse Event Assessment and Reporting  
• +120 Days (+ 3 days) post Activation  of Study Drug  
o Patient will be contacted in person or by telephone (see t elephone script - 
Appendix  3) 
o Thrombotic Assessment (via chart review)  
Page 29 of 63 
 Table 2: Study Assessments Calendar
 

Page 30 of 63 
 1- On day 1 of study treatment required laboratory tests must be drawn BEFORE the first dose of study drug is administered.  
2- To be performed daily while subject is inpatient and twice a week while  subject is outpatient - if done  more frequently per SOC, all results will be 
recorded.  
3- These tests to be performed at day of onset of ≥ gra de 2 bleeding OR at next visit following onset of ≥ grade 2 bleeding.  
4- End of Treatment (EOT) is the day when subject receives their last dose of study drug OR at next visit following last dose of  study drug.  
5- Thrombotic Assessments to be done via medical ch art review.  
6- Pregnancy test only for females of child -bearing potential (FCBP) - urine or serum (qualitative or quantitative) pregnancy test acceptable  (if not 
done within 7 days prior)  
7- Coagulation Profile is comprised of PT/INR, aPTT, Fibrinogen, D -dimer.  
8- Follow -Up Thrombotic Assessments and Adverse Event Assessment/Reporting will occur via medical record review AND  in-person or 
telephone contact with the subject.  
9- Outpatient subjects wil l be expected to maintain a daily, self -assessed bleeding diary which will be reviewed with research staff (in person or by 
phone) at least once a week . 
10- From EOT to D14 post discontinuation of study drug, inpatient subjects  will be followed via chart review for hemostatic/bleeding assessments 
and thrombotic assessments. Outpatient subjects  will complete the daily Follow -Up Self -Assessment Bleeding Diary  which will be reviewed (in 
person or by phone) with study staff at least onc e a week between EOT and D14 post discontinuation of study drug . A final diary review (in 
person or by phone) will occur once between D14 and D21 post discontinuation of study dru g and the dia ry (and any applicable Self -
Assessment Bleeding Forms) will be returned to study staff.  
11- Patient will be contacted in person or by telephone once between 14 and 21 days post discontinuation of study drug and at day  30 post 
discontinuation and day 120 post activation of study drug. If a member of the research staff is unable to contact the subject directly then their 
local physician will be contacted.  
12- Per section 11, A-TREAT ocular assessments will monitor subjects’ standard vision (Snellen Eye Char t), central visual field (Amsler Grid) and 
color perception (Ishihara test). Assessments will be done on day 1  of study drug  (no more than 72 hours before randomization up to and 
including the day of active treatment)  and will continue weekly until D14 pos t discontinuation of study drug.    
13- Patients will receive a transfusion of red blood cells per standard of care at their clinical site . 
14- Bilirubin will be collected on day 1 of activation if not completed within prior 7 days and weekly while on study drug
Page 31 of 63 
  
9. ADVERSE EVENT REPORTING  
Whenever possible, investigators should report adverse events as disease or syndromes instead of 
reporting indiv idual component symptoms, signs, laboratory abnormalities or sequelae.  
 
This study will be using the descriptive terminology developed by the National Cancer Institute for 
use in reporting adverse events: Common Toxicology Criteria for Adverse Events (CTCA E) version 
4.03, dated June 14, 2010 .  The  criteria can be found  at: 
 
http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010 -06-14_QuickReference_5x7.pdf   
 
The CTCAE includes a grading (severity) scale for each adverse event term. Grades were 
developed using the following  guidelines:  
 
Grade 1:  Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; 
intervention not indicated.  
Grade 2:  Moderate; minimal, local or non -invasive intervention indicated; limiting age -
appropriate instrumental ADL.  
Grade 3:  Severe or medically significant but not immediately life -threatening; hospitalization 
or prolongation of hospitalization indicated; disabling; limiting self -care ADL.  
Grade 4:  Life-threatening consequences; urgent intervention indicated.  
Grade 5:  Death related to AE.  
The definitions to be applied to adverse events recorded in this tr ial are given in Table 3 below.  
Table 3: Adverse Event  Definitions  
Term  Definition  
Adverse Event (AE)   Any untoward or unfavorable medical occurrence in a human subject, 
including any abnormal sign (for example, abnormal physical exam or 
laboratory finding), symptom, or disease, temporally associated with 
the subject’s participation in t he research, whether or not considered 
related to the subject’ s participation in the research.  
 
Serious Adverse Event 
(SAE)  
 Any adverse event temporally associated with the subject’s 
participation in research that meets any of the following criteria:  
• results in death1 
• is life -threatening2 
• requires hospitalization  or prolongation of existing 
hospitalization3 
• results in persistent or significant disability or incapacity 
results in a congenital anomaly/birth defect  
• any other adverse event that, based upon appropriate medical 
judgment, may jeopardize the subject’s health and may 
require medical or surgical intervention to prevent one of the 
other outcomes listed in this definition   
 
Unexpected Adverse Event  Any adve rse event occurring in one or more subjects in : 
• a research protocol, the nature, severity, or frequency of 
which is not consistent with  either t he known or foreseeable 
risk of adverse events associated with the procedures 
involved in the research that are described in (a) the protocol –
relate d documents, such as the IRB -approved research 
protocol, any applicable investigator brochure, and the current 
IRB-approved informed consent document, and (b) other 
relevant sources of information, such as product in formation 
Page 32 of 63 
 and package inserts; or  
• the expected natural progression of any underlying disease, 
disorder, or condition of the subject(s) experiencing the 
adverse event and the subject’s predisposing risk factor 
profile for the adverse event.  
 
Suspected Une xpected 
Serious Adverse Reaction  
 Any unexpected adverse event that:   
• results  in death1 
• is life-threatening2 
• requires hospitalization or prolongation of existing 
hospitalization3 
• results in persistent or significant disability or incapacity  
 
Unanticipated problem 
involving risks to subjects 
or others (UP)  Any incident, experience, or outcome that meets all of the following 
criteria:  
• unexpected (in terms of nature, severity, or frequency) given 
(a) the research procedures that are described in  the protocol -
related documents, such as the IRB -approved research 
protocol and informed consent document; and (b) the 
characteristics of the subject population being studied;  
• related or possibly related to a subject’s participation in the 
research; and  
• suggests that the research places subjects or others at a 
greater risk of harm (including physical, psychological, 
economic, or social harm) related to the research than was 
previously known or recognized.  
 
1: Death due to the underlying disease or associ ated conditions  will not be reported as a SAE.  
2: The term ‘life -threatening’ in the definition of ‘serious’ refers to an event in which the patient was at risk of death at the 
time of the event; it does not refer to an event which hypothetically might hav e cause d death if it were more severe.  
3: Hospitalization is defined as an inpatient admission, regardless of length of stay, even if the hospitalization is a 
precautionary measure for continued observation. Hospitalizations for a pre -existing condition (i ncluding elective 
procedures that have not worsened) do not constitute an SAE.  
  
Medical judgement should be exercised in deciding whether an AE is serious in other situations. 
Important AE s that are not immediately life -threatening or do not result in de ath or hospitalization 
but may jeopardize  the subject or may require intervention to prevent one of the other outcomes 
listed in the definition above, should also be considered serious.  
 
9.1 Expected Adverse Events  
9.1.1  Adverse Effects Associated with Tranexamic Acid (TXA)  
• TXA is generally well tolerated by most patients. However, it can cause side effects. 
The most common adverse reactions seen in clinical trials ( ≥ 5%, and more frequent 
in LYSTEDA® subjects compared to placebo subjects ) are headache, sinus and 
nasal symptoms, back pain, abdominal pain, musculoskeletal pain, joint pain, muscle 
cramps, migraine, anemia and fatigue. These and the following adverse events and 
other safety information are described in the Rev. 01/15 Code TX00N by AKORN 
Phar maceuticals, Inc . ® 
• Subjects may have none, some or all of the effects listed above and below and those 
adverse events may be mild, moderate or severe.  
• Patients with a previous history of thromboembolic disease may be at an increased 
risk for venous and arterial thrombosis. Although clinical evidence with tranexamic 
acid documented in published literature shows no significant increase in thrombosis, 
possi ble risk of thrombotic complications cannot be ruled out. Venous and arterial 
thrombosis or thromboembolism, as well as cases of central retinal artery and central 
retinal vein obstruction , have been reported with Tranexamic acid.  
Page 33 of 63 
 • Gastrointestinal disturba nces (nausea, vomiting, diarrhea) may occur , but have been 
shown to disappear when the dosage is reduced.  
• Giddiness  and hypotension have occasionally been reported . Hypotension has been 
observed when intravenous injection is too rapid. To avoid this respon se, the 
solution should not be administered  more rapidly than 1 mL per minute . 
• Hypersensitivity adverse events, including allergic skin reactions, anaphylactic shock 
and anaphylactoid reactions. A case of severe allergic reaction to Tranexamic acid 
was reported involving a subject on the fourth cycle of treatment. The  subject  
experienced dyspnea, tightening of the throat and facial flushing that required 
emergency medical treatment.  
• Rare ocular side effects have included disturbances of color vision a nd retinal 
venous and artery occlusion.  
• Genitourinary side effects have included ureteral obstruction due to clot formation in 
patients with upper urinary tract bleeding.  
9.1.2  Toxicities Related to Platelet Transfusions  
• Viral infections may be transmitted from the transfusion of any blood product . Donor 
blood is routinely screened for the presence of hepatitis B and C, the AIDS virus 
(HIV 1 & 2), the HTLV v iruses (1 & 2), West Nile virus  and, on occasion, for 
cytomegalovirus. In spite of testing, rare infections  with these , or other viruses , may 
still result from a transfusion.  
• Bacterial infections  can result from platelet transfusions. P latelets must be stored at 
room temperature and not in a refrigerator  so overgrowth of bacteria may occur if 
there has been a break in the sterility of the system. This could result in a serious 
infection.   
• Transfusion reactions such as chills, fever, drop in blood pressure, shortness of 
breath and, very rarely, shock can occu r due to the transfusion of any blood 
products.  On rare occasions, transfusions may be associated with a severe reaction 
that could result  in lung injury, kidney failure  or heart failure. Allergic  reactions such 
as hives, rashes or, very rarely, a severe r eaction that could result in death can also 
occur during transfusions.  
9.2 Pregnancy  and Nursing  
• The effects of tranexamic acid on embryogenesis, spermatogenesis and reproduction in 
humans are unknown. The safety of the use of tranexamic acid in women who are pregnant 
or may become pregnant has not been established. Therefore, women of childbearing 
potential and fertile men will be advised to use adequate and effective contraception from 
the time of consent to 30 days after discontinuation of study drug.  
• Patie nts who become pregnant during the study will be discontinued from study drug 
immediately and referred to an appropriate health care provider  for monitoring . The event 
will be considered a Serious Adverse Event (SAE) and will be reported per protocol section 
16.3.4.  The patient will continue to be followed per protocol, with additional follow -up for 
pregnancy outcome.  
• Tranexamic acid is excreted into breast milk, therefore  nursing subjects are excluded from 
the study. If subjects are pumping b reast milk, and the milk is destroyed, then they may be 
included.  
 
 
10. HEMOSTATIC/ BLEEDING ASSESSMENT S 
Bleeding will be recorded by the well -established bleeding assessment tool, validated in PLADO4 & 
TOPPS6 and refined for this study. Rates of recorded bleed ing are known to vary considerably 
between trials.  Reasons for this variability have been explored and published through a study 
organized by the BEST collaboration, and include different patient groups and bleeding definitions  
and variable follow up periods18.  
 
Page 34 of 63 
 In this trial, a number of measures will be taken to standardize documentation and recording of 
bleeding, including trained assessors, monitoring and education. In the recent TOPPS study, 
completeness of bleeding outcom e documentation was excellent: A bleeding assessment was 
completed on 93% (8405/9030) of days for patients in the non -prophylactic group, and 97% 
(8733/8970) of days in the prophylactic group. The majority of patients in both arms had bleeding 
information completed on each study day (median non -prophylactic 30 days (IQR 29 to 30); median 
prophylactic 30 days (IQR 30 to 30)).  
 
10.1 Inpatient Subjects  
Bleeding assessments  will be performed by means of a physical assessment of the patient, patient 
interview (if possible) , and a review of the patient chart and laboratory data. Research staff will 
perform the physical assessment and interview of the patient before  reviewing t he patient’s chart 
and laboratory data as to allow an objective assessment without the bias that might be introduced 
by performing the chart and laboratory reviews first. Research staff will perform the hemostatic 
assessment at approximately the same time each day.  
 
10.2 Outpatient Subjects  
All outpatient subjects (including those who are discharged from inpatient status prior to completion 
of the initial trial period [30 days from randomization]) will be trained in the completion of  a daily  
Self-Assessment Blee ding Diary. The diary will ask the subject to respond “yes” or “no” as to 
whether they have experienced any bleeding for each body system on that day.   Information will be 
provided to the subject describing how to report degree of bleeding in relation to amount of blood 
present, size of bruising, etc.  Subjects will have their Self -Assessment Bleeding Diary reviewed by 
research staff at least weekly, either in person or over the phone. Patients who are seen in the 
outpatient clinic whilst still within the 30 day trial period will have a bleeding assessment completed 
by the local research staff  in addition to the daily self -assessment . Self-assessment data  will not be 
used as the outcome unless there is no medical assessment form.  
 
All outpatient subjects will  be contacted by the research staff between day 14 and 21 post 
discontinuation of study drug a diary review and to c onfirm arrangement s to collect al l relevant 
forms. All forms will  be entered  into the trial database.  
 
11. SAFETY  ASSESSMENTS  
Thrombotic assessments will be performed via a review of medical chart notes and imaging studies  
by trained research staff at the following time points (see Table 2: Study Assessments Calendar for 
further information regarding timing of assessments):  
11.1 Thrombotic Assessments  
     11.1.1 Inpatient Subjects  
11.1.1a  Weekly  in the days between Day of Enrol lment and Day of Randomization  
11.1.1b  Day of Randomization  
11.1.1c  Daily  during active treatment with study drug  
11.1.1d  Day 30 post first dose of study drug  
11.1.1e  End of Treatment  
11.1.1f  +1 day post last dose of study drug  
11.1.1g  At least Once between 14 and 21 days post discontinuation of study drug  
11.1.1h  Day 30 post discontinuation of study drug  
11.1.1i  Day 120  post activation  of study drug  
 
11.1.2 Outpatient Subjects  
11.1.2 a Weekly  in the days between Day of Enrollment and Day of Randomization  
11.1.2 b Day of Randomization  
11.1.2 c Twice a week during active treatment with study drug  
11.1.2 d Day 30 post first dose of study drug  
11.1.2 e End of Treatment  
Page 35 of 63 
 11.1.2 f +1 day post last dose of  study drug  
11.1.2 g At least Once  between 14 and 21 days post discontinuation of study drug  
11.1.2 h Day 30 post discontinuation of study drug  
11.1.2 i Day 120 post activation  of study drug  
 
11.2 Ocular  Assessments  
11.2.1  All subjects will have ocular assessments of standard vision using the Snellen Eye  
       Chart, central visual field using the Amsler Grid, and color perception using the    
       Ishihara color plates no more than 72 hours before randomization up to and including     
       the day of active treatment, then weekly until two  weeks post discontinuation of study     
       drug.  
11.2.2   Subjects should be instructed to report visual and ocular symptoms pro mptly to  
       study staff , and to have a vision check by study staff or physician thereafter.  
      11.2.3 Rationale:  The package inserts for both oral (LYSTEDA) and IV (CYKLOKAPRON)   
             TXA include warnings for ocular and visual changes that have been observed in both   
             Pre-clinical animal studies and post -marketing surveillance. The package insert notes  
             that no  such changes were observed during clinical trials involving treatment for   
             weeks to months  of TXA, however it does recommend monitoring of visual acuity at  
             regular intervals, with  discontinuation of therapy if visual or ocular symptoms occur.  
 
       11.2.4 In this study, the patients will often be receiving c hemotherapies and steroids that  
              are associated with similar visual and ocular changes, tho ugh the exact incidence of  
              such  changes is not well -characterized. Through the specified monitoring of v isual 
              and ocular  signs and symptoms, we address the possibility that TXA migh t      
              exacerbate the effects of the  chemotherapies. All visual or ocular AEs that are       
              CTCAE Grade 3 or higher will  be reported to the independent DSMB in an expedited    
              fashion,  in order that any  differential  incidence of such changes across treatment    
              arms can be assessed  and lead to protocol  changes as appropriate.  
 
12. LOSS TO FOLLOW UP  
12.1 Death  
Death  will be recorded on the end of study form and will be characterized by time from consent and 
according to whether the investigator attributes  mortality due to bleeding , due to thrombosis , or due 
to other causes . 
 
12.2 Withdrawals  
Subjects are free to stop study drug at any time. If this occurs, t he date and time that study drug is 
voluntarily stopped will be recor ded, along with the reason the subjec t so elected. In the event the 
subjec t elects to stop study drug, they will still be followed for all study o utcom es according to study 
protocol.  
 
Subject s are also free to withdraw their consent for further participation in the trial at any time. If this 
occurs, subjects  will be asked to grant consent for the study team  to passively monitor their clinical 
outcom es for major clinical events. In order to avoid any doubt, if subjects withdraw consent it will 
be explained  to them that any data obtained up to the point of consent withdrawal will be included in 
study analysis, regardless  of their consent for future mon itoring .  
 
An End of Study  form will be completed, which wil l detail whether the subject is:  
12.2.1  Stopping study drug , but continuing all other protocol speci fied procedures and 
monitoring.  
12.2.2  Stopping study drug and protocol specific procedures and monitoring , but allowing 
passive monitoring of their medical record and follow -up for vital status 30 days after  
their last dose of study drug . 
12.2.3  Discontinuing all further contact with study investigators.    
Page 36 of 63 
  
The patient’s physician or the principal investigator may withdraw the patient from the study  for any 
reason . 
 
An End of Study form  will be completed and the reason for withdrawal recorded if possible  for all 
occurrences .  
 
13. END OF STUDY  
Subjects will exit the study after the day 120 post activation  of study drug time point requirements 
are fulfilled.  
 
14. STATISTICAL CONSIDERATIONS  
14.1 Rationale and Objectives  
The hypothesis is that in patients with hematologic malignancies, during a period of se vere 
thrombocytopenia, prophylactic use of anti -fibrinolytic therapy with TXA would decrease bleeding 
and the demand for platelet transfusions. Additional benefits for patients might extend to improved 
in-patient experience and earlier discharge home.  
14.1.1  Primary Efficacy Endpoint - Assessment of the TXA effect on bleeding will primarily 
consider the difference in the proportion of patients on each arm having bleeding of WHO 
grade 2 or above at some point during the first 30 days post activation  of study dru g.  
14.1.2  Secondary Efficacy Endpoint s- Assessment of the TXA effect on demand for platelet 
transfusions will primarily consider the difference between the treatment arms in the average 
number of platelet transfusions per patient during the first 30 days post activation  of study 
drug. A composite endpoint incorporating both bleeding and all cause mortality will consider 
the difference between the treatment arms in the average number of days alive without 
WHO grade 2 bleeding or greater during the first 30 days af ter activation. In order to protect 
against inflation of the type 1 error, a closed testing procedure will be used in which the 
statistical significance of any observed effects of TXA on the secondary endpoints  will only 
be interpretable if a statistically  significant effect of TXA on the primary efficacy endpoint is 
observed.  
14.1.3  Supportive and Exploratory Efficacy Endpoints - Additional endpoints examining other 
measures of bleeding, transfusions, and clinical outcomes associated with TXA treatment 
will be use d to further support any statistically significant effects observed for the primary 
and secondary efficacy endpoints. The statistical significance of these additional endpoints 
will not be directly interpretable owing to the multiple comparisons.  
 
14.2 Randomiz ation  
Patients will be randomized to antifibrinolytic therapy with TXA or to placebo in a 1:1  
fashion, stratified by site  and disease group (allogeneic transplant, autologous transplant, or 
leukemia) . Randomization will further be balanced within blocks of varying,  
undisclosed sizes.  
 
14.3 Analysis Populations  
Subject s will be grouped according to randomization gro ups: TXA versus placebo. Unless  
otherwise  specified, all efficacy analyses will be by a modified intention to treat (mITT ) 
strategy among activated subjects as described below. All subjects who were activated to  
study  drug will be included in the analyses in the tre atment group to which they were randomly 
assigned.  Subjects who were activated for  study drug will be included  in the  
analyses, even if they stop study drug “early”, cross ov er between treatment groups, or  
receive prophylactic transfusions not in accordance with the protocol.  
14.3.1  Efficacy Population  
    The mITT population used for efficacy analyses will be comprised of all randomized  
    patients for whom an order for administration of study drug is activated . Efficacy  
Page 37 of 63 
     analyses on these patients will use data gathered from th e time the order for study drug  
    was activated  until 30 days post activation . Randomized patients who d evelop exclusion  
    criteria prior to activation  of study drug and who thus ar e excluded from receipt  of study  
    drug and patients whose platelet counts never d rop below the 30K threshold for  
    activation  of study drug will not be included in the primary efficacy population.  
 
    Rationale:  Owing to the emergent nature of treatment of thrombocytopenic patients,    
    patients are randomized in a double blind fashion to t he treatment arms when platelet  
    levels drop below 50K. Because the treating physicians are blinded to tr eatment arm  
    assignment, no bias in activation of  the study drug is anti cipated. By using the time that  
    the study drug is activated  as the criterion for inclusion in the mITT  population, we guard  
    against differential delays in pharmacy preparation of placebo versus study drug.  
14.3.2  Safety Population  
The population used for safety analyses will be all patients who receive any amount of study 
drug. Follow -up for mortality and thrombotic events will occur at 120 days post activation. 
Other adverse events and serious a dverse events will be collected for 30 days post 
discontinuation of study drug, with visual examinations occurring weekly for two weeks after 
discontinuation of study drug. SOS (VOD), AEs, and SAEs will be based on clinical 
diagnosis and patient report dur ing the surveillance period. The frequency of follow -up will 
differ between inpatients and outpatients, with the former based on daily visits by the 
research coordinators and the latter based on patient diaries and semiweekly clinic visits 
(while still on study drug) or weekly contacts (after discontinuation of study drug  
 
14.4 Competing Risks  
14.4.1  Death  
     Owing  to the seriousness of the patients’ underlying medical condition and based on  
     PLADO data it is anticipated that fewer than 5%  of patients migh t die from their disease or its  
     treatment prior to full determination of the primary an d/or secondary endpoints (e.g.,  
     dying within 30 days without experiencing significant bl eeding). Such “competing risks”  
     pose both scientific and statistical dilemmas. In terms of t he scientific aims, the primary  
     analysis of A-TREAT data will use an approac h that  presumes independence of death  
     and future bleeding that is conditional on the hematologic and t ransfusion history for  
     patients  prior to death. The interpretation of the resulting compa risons is as an estimate of     
     the effect of TXA  on bleeding rates in a population in which the treatment of the underlying  
     medical condition (e.g., infections secondary to ch emotherapy) has improved to the  point that  
     patients are no longer at risk of early death. Th e statistical treatment of  this approach is  
     described in 14.5.  
 
     Rationale: There is of course no way to know whether  patients who die early have an  
     increased  or decreased propensity to bleed in the absence of the competing risk.  
     Ultimately, the impact of the proposed “missing -at-random” (MAR) analysis of these  
     incomplete observations will have to be examined in a  series of sensitivity analyses  
     described in 14.5.4. Alternative strategies considered by the A-TREAT in vestigators  
     included using death as a part of a composite endpoint  that includes bleeding and all  
     cause mortality. However, such an analysis does not truly protect against the  possibility  
     that a treatment might cause a minor increase in death and a more ma jor decrease in  
     bleeding rates. Even with a composite endpoint the ove rall mortality rates would thus  
     need to be examined separately  and there could even be nonsignificant trends toward  
     increased mortality on TXA that would have to be considered carefully. Hence, the A 
     TREAT investigators decided on an approach consistent  with their clinical impression  
     that there was not  a strong dependence betw een death from other causes and  
     propensity to bleeding, and to use the seconda ry and supporting endpoints and  
     sensitivity analyses to explore the robustness o f the analysis results to other  
     assumptions  
14.4.2  Discharge from  Hospital  
Page 38 of 63 
 Patients  discharged from the hospital prior to 30 days post randomization will not have as 
intense surveillance for study events as will those who remained in the hospital. They will 
have completed a daily bleeding diary and be contacted to determine any clinicall y important 
bleeding events. Absence of a bleeding event that leads to hospitalization or treatment by 
doctor/healthcare worker or categorized as such in the daily bleeding diary will be judged as 
absence of grade 2 or higher bleeding by WHO criteria. Simi larly, such patients will be 
imputed to have not had transfusions.  
 
14.5 Statistical Analysis Models  
All statistical inference will be based on a two -sided 0.05 level of significance and two -sided 95% 
confidence intervals.  Full details regarding statistical ana lysis models will be presented in a 
Statistical Analysis Plan completed prior to the first unblinded analysis of the data.  
14.5.1  Primary Endpoint  
The odds of bleeding at WHO grade 2 level or above will be analyzed in a logistic regression 
model adjusting for tre atment arm , clinical site as a factored variable , and disease group 
(allogeneic transplant, autologous transplant, or leukemia) as a factored variable. . The test 
statistic will be based on the score statistic for the treatment arm parameter from the logist ic 
regression model with adjustment for multiply imputed missing data.  
14.5.2  Secondary Endpoint s 
The secondary endpoints of mean number of platelet transfusions and the mean number of 
days alive without WHO grade 2 level or above bleeding will each be analyzed i n a linear 
regression model adjusting for treatment arm , clinical site as a factored variable , and 
disease group (allogeneic transplant, autologous transplant, or leukemia) as a factored 
variable . The test statistic will be based on the Wald statistic (par ameter estimate divided by 
its standard error) as computed for the treatment arm parameter  from the linear regression 
model using the Huber -White sandwich estimator for standard errors to account for possible 
heteroscedasticity and adjusting for multiply i mputed data.  
14.5.3  Additional Analyses  
Analysis  of the supportive and exploratory endpoints will be conducted using regression 
models adjusting for treatment arm , clinical site as a factored variable , and disease group 
(allogeneic transplant, autologous transplant, or leukemia) as a factored variable . Linear 
regression will be used for endpoints measuring the days free of bleeding and highest grade 
of bleeding, logistic regression will be used for binary endpoints, and proportional hazards 
regression will be used for times to event. The Huber -White sandwich estimator of the 
standard error will be used to allow for departures from the model based variance estimates, 
and adjustment will be made for multiply imputed missing data.  
14.5.4  Missing Data  
Patie nts will be followed for all clinical trial outcomes regardless of their adherence to the 
prescribed regimen for the study drug (TXA or placebo). Very few patients are expected to 
withdraw consent, though there will undoubtedly be some cases in which the d ata are 
missing for one or more of the primary, secondary, or supporting analyses due to withdrawal 
of consent or competing risks as described in 14.4.  
 
Initial analyses of primary and secondary endpoints will be based on missing -at-random 
(MAR) models th at condition on the patients’ prior history of platelet levels, platelet and red 
blood cell transfusions, and days since activation  of study drug. In the MAR model, data will 
be imputed by assuming that patients with missing data will be presumed to have 
distributions of outcomes the same as that observed in comparable patients who have 
complete data.  
 
Sensitivity analyses will use missing not at random (MNAR) models to reflect increased or 
decreased odds of bleeding among patients with incomplete data. Each treatment arm will 
be parameterized separately, and the robustness of any estimated treatment eff ect to those 
varying levels of dependence between early death or withdrawal of consent and incidence of 
Page 39 of 63 
 bleeding will be quantified. Additional models will consider separate mechanisms for early 
death and withdrawal of consent.  
 
14.6 Sample Size and Precision o f Statistical Inference  
14.6.1  Minimal Clinically Important Difference  
Based on  results observed in the PLADO study for patients who meet the general eligibility 
criteria for the A-TREAT  study, it is anticipated that 57% of eligible patients would 
experience WHO Grade 2 bleeding or higher in the absence of antifibrinolytic therapy. In 
such a background setting of bleeding, the study investigators anticipate that less than a 
10% relative r eduction in bleeding rates would not be sufficient to substantially change 
clinical practice, because the absolute risk reduction of 5.7% would mean that it would be 
necessary to treat approximately 17.5 patients in order for the treatment to have impact o n 1 
patient (“Number Needed to Treat” (NNT) = 17.5). As much as a 25% relative reduction in 
bleeding rates would likely be judged sufficient to change clinical practice, because with an 
absolute risk reduction of 14.25%, the NNT of approximately 7 patients  might be acceptable, 
provided no new safety issues related to antifibrinolysis in the thrombocytopenic population 
are uncovered. The A-TREAT investigators hypothesize that TXA will be associated with a 
relative reduction of 30% or higher (absolute reducti on of 17%) based on observational data 
relative to their prior clinical experience.  
14.6.2  Sequential Stopping Rules  
The conduct  of the A-TREAT  study will be overseen by an independent Data and Safety 
Monitoring Board (DSMB) who will enhance patient safety by mon itoring study progress and 
integrity, incidence of AEs and SAEs, and interim estimates of treatment effect on bleeding. 
The DSMB will be guided by a group sequential stopping rule to judge the scientific and 
statistical credibility of interim results on th e bleeding endpoints.  
 
While the exact stopping rule will be chosen in discussion with the DSMB  (and documented 
in the Statistical Analysis Plan finalized prior to the first interim analysis at which the DSMB 
will see unblinded data) , the A-TREAT  investig ators propose a stopping rule that would allow 
early stopping only if a one -sided level  0.20 O’Brien -Fleming stopping boundary suggested 
that TXA was associated with more bleeding than placebo. There would be no early stopping 
boundary for efficacy of TXA over placebo , with the final critical value for efficacy providing a 
one-sided 0.025 level of significance .  
 
The following table presents example stopping boundaries that might correspond to an 
observed combined event rate of 0.485 (such as might be observed with 57% events on the 
placebo arm and 40% events on the TXA arm). Using the R package RCTdesign (or 
equivalently, S -Plus S+SeqTrial),  a stoppi ng boundary having three  analyses  at 50%, 75% 
and 100% of the planned sample size and with a level 0.2  O’Brien -Fleming boundary for 
harm would be computed using the RCTdesign code:  
 
 seqDesign( prob.model  = "prop", null.hypothesis  = 0.57, 
  alt.hypothesis  = 0.4, nbr.analyses  = 3,  
  sample.size  = c(165, 248, 330), test.type  = "two.sided" ,  
      power = "calculate" , alpha = c(0.025, 0.2),  
   P = c(Inf, 1)) 
 
For this example stopping boundary, the following table presents the critical values for harm 
and the corresponding adjusted statistical inference at each of the formal interim analyses. 
Critical values are expressed in terms of the crude estimate of treatment effect (TXA 
bleeding rate minus control bleeding rate), a Z statistic, and a one -sided fixed sample P 
value testing for harm. The adjusted statistical inference is a point estimate based on the 
bias adjusted mean and 95% confidence intervals and one -sided P values testing for harm 
using the likelihood ratio ordering of the outcome space.  
Page 40 of 63 
 Analysis  Stopping Boundaries  Adjusted Inference  
 N Crude  
Estimate  Z Fixed  
P val  Estimate  95% CI  One-sided  
P value  
50% 165 0.111  1.440  .075 0.095  (-.004, .181)  0.123  
75% 248 0.074  1.175  .120 0.059  (-.018, .132)  0.178  
100%  330 0.055  1.019  .154 0.043  (-.022, .115)  0.200  
 
Rationale: Owing to the need for adequate safety data, even if TXA is associated with 
markedly less bleeding than placebo, there is an imperative to gather safety data on the full 
sample size. Because TXA is currently being used off-label in the thrombocytopenic setting, 
it is important to document any harm due to TXA treatment, rather than just documenting the 
absence of a markedly beneficial effect . 
 
14.6.3  Sample Size  
Calculation of sample size and statistical power were made using S+ SeqTrial based on the chi -
squared test of association, which is equivalent to the score test from simple logistic regression. 
Based on 1:1 randomization, a one-sided level of significance 0.025, a design alternative 
hypothesis of 30% relative reduction in bleeding rates (57% on the placebo arm and 40% on 
TXA), a sample size of 330 subjects (165 TXA, 165 placebo) will provide 88% statistical power 
to declare statistical significance on the primary endpoint. This sample size will provide 74.8% 
statistical pow er to detect a 25% relative reduction in bleeding rates (57% vs 42.75%).  
 
14.6.4  Precision of Inference for Efficacy  
With the planned sample size and a placebo bleeding rate of 57%, an observed absolute 
decrease in WHO grade 2 or above bleeding of 10.6% (so 57% o n placebo, 46.4% on TXA) 
would be judged statistically significant. Such an absolute difference in rates corresponds to 
a NNT of 9.4. If the baseline placebo bleeding rate were instead 40%, the threshold for 
statistical significance would be an absolute re duction of 10.14% (NNT = 9.9), and a 
baseline placebo rate of 70% would have a threshold of 10.35% (NNT = 9.7). These results 
are judged to be of the magnitude to possibly affect clinical practice, and allow for some 
added loss of precision with multiply i mputed missing data.  
14.6.5  Precision of Inference for Safety  
This study is not powered to establish the definitive safety of the treatment with respect to 
the frequency of VTE. However, an observed difference in frequency of VTE of 3.7% on the 
placebo arm and 5.5% or less on the TXA therapy arm would result in a 95% confidence 
interval that excluded a relative risk of 3.0.  
 
14.7 Feasibility of Recruitment  
The three clinical sites have proven success recruiting patients in the PLADO study at a rate that 
would predict  success in achieving accrual of 330 activated patients during the planned 4 year 
accrual period.  
 
The following table documents how that prior success translates into the A-TREAT  targeted 
enrollment:  
 
 PLADO  
(3.5 yr)  Annualized  
Rate  Four Year  
Projections  A-TREAT  
Target  
Puget Sound Blood Center  at the 
University of Washington  107 30.6 122 110 
University of Pittsburgh  119 34.0 136 110 
University of North Carolina  99 28.3 113 110 
Total  326 92.9 371 330 
 
It can be seen that, based on annualized rates achieved in the PLADO study by these sites, there is 
12% excess capacity.   
Page 41 of 63 
  
If accrual to the study does not meet expectation additional sites will be recruited.  
 
15. TRIAL MONITORING  
15.1 Clinical Site Monitoring  
Study monitoring will be the responsibility of the Data Coordinating Center (DCC).  Upon successful 
approval of the protocol and establishment of the regulatory file, the clinical monitor will establish a 
clinical mo nitoring plan. To ensure that  the investigator and the study staff understand and accept 
their defined responsibilities, the clinical monitor will maintain regular correspondence with the site 
and may be present during the course of the study to verify the acceptability of the facilit ies, 
compliance with the investigational plan and relevant regulations, and the maintenance of complete 
records.  
 
Monitoring visits by a sponsor’s representative -designated clinical monitor will be scheduled to take 
place during the study at appropriate in tervals and after the last subject has completed the study. A 
report of monitoring observations will be provided to the site PIs for corrective actions . 
 
15.2 Direct Access to Data  
Study subjects will be identified on CRFs by a unique study subject ID code and on source 
documents by name or study subject ID code. No personal identifier will be used in any publication 
or communication used to support this research study. The study subject ID code will be used in the 
event it becomes necessary to identify data spe cific to a single study subject. Representatives from 
the DCC, IRB and the FDA are eligible to review medical and research records related to this study 
as a part of their responsibility to protect human study subjects in clinical research. Medical and 
research records will be de -identified before being photocopied. Study results will not be given to 
individual subjects but will be published in the open literature and made available as a matter of 
public record . 
 
15.3 Audits and Inspections  
Authorized  representatives of the sponsor , IRB or FDA  may visit the site to perform audits or 
inspections, including source data verification. The purpose of the audit or inspection is to 
systematically and independently examine all study -related activities and docum ents to determine 
whether these activities were conducted, and data were recorded, analyzed, and accurately 
reported according to the protocol, ICH GCP, and any applicable regulatory requirements.  
 
The investigator should contact the sponsor’s representati ve and DCC and the study sponsor 
immediately if contacted by a regulatory agency about an  inspection . 
 
15.4 Source Data Verification  
A monitoring plan between the sites and the Data Coordination Center will be written and followed. 
A proportion of the CRF data will be checked against source  documentation , including 100% of the 
first three patients recruited to the study at the site and key endpoint data  of all patients recruited 
thereafter .  Particular attention will be paid to those patients who experience Serious Adverse 
Events and/or  Serious Transfusion Reactions. All CRF data, whether or not subject to source data 
verification, will be checked by each site for completeness and consistency before being sent to 
data management. All consent forms will be mon itored.  
 
15.5 Quality Assurance and Quality Control of Data  
In addition to source data verification, quality control of the clinical bleeding assessments will be on -
going throughout the trial. This will include initial training of the clinical study staff, trai ning of 
patients in proper self-assessment, and a program of duplicate bleeding assessments to ensure 
consistency in completion of the clinical bleeding assessment forms. Standard guidelines will be 
followed.   
 
Page 42 of 63 
 Good Clinical Practice Guidelines require th at investigators maintain information in the subject’s 
medical records, laboratory reports, clinical charts etc. that corroborate data recorded on the CRFs. 
In order to comply with these source documentation requirements, the following in formation should 
be maintained:  
• Medical history/physical condition of the subject before enrollment sufficient to verify protocol 
entry criteria . 
• Dated and signed notes for specific results of procedures and exams.  
 
15.6 Confidentiality  
Data will be held securely in locked files  or an encrypted database at the DCC and at each trial site.   
 
Patients will be identified only by study specific identification number on all data that are sent to the 
DCC.  
 
No personal identifier will be used in any publication or communication used to  support this research 
study. The study subject’s ID code will be used in the event it becomes necessary to identify data 
specific to a single study subject.  
HIPAA requires that researchers obtain the study subject’s permission (HIPAA Authorization) to use 
and disclose health information about the subject that is either created by or used in connection with 
this research. The information includes the entire research record and supporting information from 
the study subj ect’s medical records, results of laboratory tests, and both clinical and research 
observations made during the study subject’s  participation in the research.  
 
In this research, the study subject’s health information will be collected and used to conduct t he 
study; to monitor the study subject’s health status; and any adverse events. Health information is 
used to report results of research to the sponsor’s representative and federal regulators and may be 
reviewed during study audits for compliance with stud y plans, regulations, and research policies. 
After the study ends, each study subject has the right to see and receive a copy of his or her 
information.  
 
The site PIs will be responsible for retaining sufficient information about each study subject, that is 
name, address, telephone number, and identity in the study, so that the sponsor’s representative, 
and other regulatory authorities may have access to this information should the need arise.  
 
 
15.7 Ethical Conduct of the Study  
This study will be  conducted in accordance with 21 CFR Part 50 and the Belmont Principles of 
respect for persons, beneficence, and justice.  
 
The procedures set out in this study are designed to ensure that the sponsor’s representative and 
all study personnel abide by the pr inciples of the ICH GCP Guideline and the CFR. The co -PIs 
confirm this by signing this study protocol.  
 
16. RECORDS AND REPORTS  
16.1 Case Report Forms  
The study will used a web based data entry system.  
 
Case Report Forms (CRFs) will be used to collect all subject study data during the course of the 
study. The Principal Investigator at each clinical site or a predetermined designated individual shall 
be responsible for completion of the CRFs. All protocol devia tions shall be documented and a 
justification for any missed assessments shall be provided on the protocol deviation log. Completion 
of the CRFs will be on -line via a secure password protected website.  Queries will be resolved via 
the secure web based dat a entry system; those that cannot be resolved in this way will be 
completed via  email or phone communication and correct ions will be made to appropriate CRFs .  
Page 43 of 63 
 The Investigator will allow NHLBI, the FDA, or other regulatory bodies to review the study files , 
subject CRFs, medical records and other study -related documents.  
 
16.2 Record Retention  
The sites must maintain the signed Informed Consent Forms, CRFs, study documentation (listed 
above) and source documents for at least 3 years after study completion or termination. In the event 
of an FDA audit, the Investigator must allow FDA access to the study records for inspection and 
copying . 
 
16.3 Data Management  
Data will be collected by individual sites and provided to the DCC in the manner described below.  
16.3.1  Data Entry  
The DCC will provide secure web-based HTML forms to collect necessary information from 
the participating sites. Web entry forms will have dynamic features such as immediate 
checks on data and relationships within a form and between forms. Details and clarification 
about data items will be provided using pop -up windows and links to appropriate se ctions of 
the on -line version of the Manual of Operations. Data encryption and authentication methods 
will be used. Additional features of the web entry forms will include: form transmission 
history, access to past forms, tracking of data corrections, and the capability to save and re -
load incomplete forms.  
16.3.2  Database Management  
The DCC will use a two -tiered database system. A front -end database serves the web entry 
needs, using a database management system well -suited to handling updates from multiple 
intera ctive users. The data from this database will be transferred periodically (e.g. weekly) to 
a data format that can be utilized by statistical software packages. These will be the basis for 
queries, analyses and monitoring reports.   Database files will be ma intained on a password 
protected computer in a secure location behind a firewall.  
Various versions of the database are kept as needed, e.g. for quarterly performance reports. 
Back -ups of data and programs will be performed regularly. Access to data will be  limited to 
those who need access to perform their tasks.  
16.3.3  Trial Specific Exceptions to Expedited SAE Notification and Reporting  
All deaths will be reported on the end of study data form.  Although  death as a result of 
disease progression is not an SAE  it will be reported within 24 ho urs to the DCC, see section 
16.3.4).    
 
Due to the seriousness of the disease in this study, the following situations that would fulfil 
the definition of an SAE are excluded from expedited notification and may be reported to the 
DCC within 5 working days.  
• Elective hospitalization to simplify treatment or procedures  
• Elective hospitalization for pre -existing conditions that, in the investigator’s opinion, 
have not been exacerbated by trial treatment  
• Admission to the intensiv e care unit related to the disease  
• Severe Sepsis  
• Disease Progression  
• Any other serious event related to the underlying disease or medication used to treat 
the disease  
16.3.4  Serious Adverse Events  
All serious adverse events, including death of a n actively  partici pating subject, must be 
reported to the DCC within 24 hours  by e-mail. This will allow investigation into the cause of 
death to determine if it was a result of disease progression or potential SAE.  The 
Serious/Unexpected Adverse Event Form must be sent to the DCC within 48 hours . The 
Serious Adverse Event Form will be entere d into the web based data entry system by the 
site and further information and follow up will be prompted by the DCC via the SAE 
adjudication system in place .  
Page 44 of 63 
  
Serious adverse events, including death, will be monitored continuously by the DCC as data 
are received.  
 
When a transfusion related adverse reaction/event or other medical event occurs, the 
investigator responsible for the care of the patient must first assess whether the event is 
serious using the definitions given in Figure 3 (section 9).  
 
The clinical staf f responsible for the care of the subject remains responsible for reporting all 
adverse transfusion reactions/events according to normal procedures.  
 
Information about the following events will be collected:  
• Serious adverse events, regardless of attributed  relationship to study drug, that occur 
after consent is signed.  
• Any unexpected adverse events (all grades), attributed as possible, probably or 
definitely related to the study drug.  
 
The investigator must assess the causality of all Serious Adverse Events  using the 
definitions in Table 4 .  
 
If the causality assessment is deemed unrelated the event is classified as a SAE.  
 
If the causality is assessed as either possibly, probably or definitely related then the event is 
classified as a Serious Adverse React ion. 
 
Table 4: Definitions of Causality/ Attribution  
Relationship  Description  
Unrelated  There is no evidence of any causal relationship.  
Event clearly related to other factors (e.g., clinical 
state, other  therapies; concomitant drugs).  
 
Possible  There is some evidence to suggest a causal 
relationship (e.g. because the event occurs within a 
reasonable time after administration of the trial 
treatment). However, the influence of other factors 
may have contri buted to the event (e.g. the 
patient’s clinical condition, other concomitant 
treatments).  
 
Probable  Sequence of event is compatible with study drug, 
device, or procedure and cannot be explained by 
other factors without much doubt  
 
Definitely  Sequence of event is compatible with study drug, 
device, or procedure and beyond doubt cannot be 
explained by other factors  
 
If the event is an SAE the Investigator must assess the expectedness of the event  as well .  
 
  
Page 45 of 63 
 Figure 5:  Investigator Assessment of Adverse Events  
The DCC should be notified within one working day of the investigator becoming aware of an 
event that requires expedited reporting (i.e. any expected or unexpected Serious Adverse 
Reaction or other serious event such as a major bleed [gr ade 3 or 4]). Investigators should notify 
the DCC of all such events occurring during the study period.  
 
The SAE form must be completed by the Investigator (consultant/physician named on the 
signature list and delegation of responsibilities log who is responsible for the subject ’s care), 
with due care being paid to the grading, causality and expectedness of t he event as  outlined 
above. In the absence of the responsible investigator the form should be  completed and signed 
by a member of the site trial team. The responsible investigator sh ould subsequently check the 
SAE form, make changes as appropriate, sign an d then upload to the web site, or re-fax/hand 
deliver to the DCC as soon as possible. The initial report shall be followed by detailed, written 
reports as requested by the DCC.  
 
Follow -up: Subjects  must be followed -up until clinical recovery is complete an d laboratory 
results have returned to normal or baseline, or until the event has stabilized . Follow -up should 
continue after completion of the study period if necessary. Follow up information may be 
provided to the DCC on a separate form provided once a SA E report form has been received. 
The subject  must be identified by trial number only. The subjec t’s name must not be used on 
any correspondence.  
 
Site staff must notify their local IRB of any event that is classified as a suspected unexpected 
serious adver se reaction (as per the institutions standard local procedure).  
 
DCC Responsibilities : The Primary Investigator or a medically qualified delegate will review all 
SAE reports received. The causality assessment given by the local Investigator at the hospital 
cannot be overruled and in the case of disagreement, both the opinions of the patient’ s 
physician and the trial site PI will be provided in any subsequent reports. All SAE reports will be 
reviewed by the DSMB , as directed by the DSMB  and as a listing at their  review of the trial every  
6 months . 
 

Page 46 of 63 
 17. INSTITUTIONAL REVIEW BOARD (IRB)  
No subject will be enrolled into the study until the IRB has approved the protocol and the informed 
consent form. Copies of all submissions to and correspondence (approvals and disapprovals) from 
the IRB must be maintained in a regulatory file at the study si te. 
 
18. TRIAL COMMITTEES  
18.1 Trial Steering Committee (TSC)  
A Trial Steering Committee will provide oversight of this trial, which will be conducted according to 
the principles of GCP. Members of the TSC include PIs from the trial sites and the PI of the DCC.  
 
18.2 Data and Safety Monitoring Board (DSMB)  
The conduct of the trial and the safety of patients accrued to the trial will be monitored by an 
Independent DSMB agreed upon by the NHLBI . Membership will be independent of study 
investigators and have no financial or intellectual conflicts of interest. The DSMB will be comprised 
of 4-6 members, including hematologists, a biostatistician, and an ethicist.  The DSMB will be 
guided by a DSMB Charter that delineates the roles and responsibilities of the DSMB, including 
delineation of the lines of communication between study clinical investigators, study data 
coordinating center, and the NHLBI.  
 
The DSMB will meet via teleconference every 6 months to review study progress (recruitment, 
adherence to protocol) and safety da ta, including serious adverse events, adverse events, bleeding 
events, and mortality. The DSMB may also request more frequent meetings as necessary to protect 
study integrity and study safety.  
 
Page 47 of 63 
 APPENDIX 1: TRANEXAMIC ACID AND EPSILO N AMINOCAPROIC ACID STUDIES  
Table 1: Tranexamic Acid Studies (Characteristics)
Study  Type of 
study  No. of 
pts No. of pts 
receiving 
TA No. of pts plt 
refractory/ 
allo-
immunization  Diagnosis of 
pt Treatment 
of 
underlying 
disease  Tranexamic 
acid dose  Tranexamic 
acid 
frequency  Tranexamic 
acid route  Treatment 
started  Treatment 
stopped  Platelets 
given  
Randomized studies  
Avvisati 
1989 [19] RCT 12 6 NR 
 APL Chemo  2g 8hrly  IV in 500ml 
5% glucose  1st day of 
antileukemic 
Rx After 6 days  Prophylactic  
Fricke 
1991 [20] RCT 
Cross -
over 8 Only 
3 
complet
ed 
study  8 At least 3  7 AA  
1 MDS  NR 20mg/kg  8hrly  Oral After 4 day 
trial period to 
assess drug 
tolerance  Successive 
4/52 
courses or 
until grade 2 
bleeding  Therapeutic  
Shpilberg 
1995 [12] RCT 56 26 NR AML 
38 induction  
18 
consolidation  Chemo  1g 6hrly  Oral Platelets < 20 
or rapidly 
falling and < 
50 Platelet 
count > 20 
for 2 
consecutive 
counts  Therapeutic  
Non-randomized studies  
Ben-Bassat 
1990 [21] Not 
controlled  54 54 NR Newly 
diagnosed 
AML Chemo  1g 6hrly  Oral 
IV if unable 
to tolerate 
PO Platelet count 
< 50 Platelet 
count > 20  Therapeutic  
Sanz  2010 [22] Historical 
control  732 560 NR Induction APL 
patients  Chemo  100mg/kg/day  Continuous 
infusion  IV Platelets <50  Platelets > 
50 Prophylactic  
>30 
 
Page 48 of 63 
 Table 2: Tranexamic Acid Studies (Results)  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
†This study had major methodological limitations and any results should be treated very cautiously.  
* It could not be determined whether the higher incidence of bleeding in the TXA arm was due to the higher number of days pat ients were on the study prior to failure as this was not reported.  Study  Type of study  No. of pts  Diagnosis of 
patient  Thrombotic risk  Bleeding  Death due to 
bleeding  Platelet 
transfusions  Platelets 
given  
Randomized studies  
Avvisati 1989 [26] RCT 12 APL No 
thromboembolic 
events observed  Cumulative 
hemorrhagic 
scores  
TA 3  
C 42  
(P = 0.0045)  Not reported  Extra platelet 
Tx 
TA = 69 Tx  
C = 222 Tx  
 
P = 0.045  
 Prophylactic  
Fricke 1991 [38]† RCT Cross -over 8 Only 3 
completed 
study 7 AA  
1 MDS  Not reported  No evidence for 
difference in 
bleeding from 
mouth (p >0.2) or 
nose (p = 0.07). 
TXA more 
bleeding for skin 
(P<0.02)*  1 patient died 
from ICH 4 days 
after starting Rx  Failure for 
each section 
of the study 
was need for 
plt Tx  
TA 8/26  failed  
C = 9/23 
failed  Therapeutic  
Shpilberg 
1995 [27] RCT 56 AML 
38 induction  
18 consolidation  No 
thromboembolic 
events observed  Induction  
TA 6.2±2.9  
C 4.5±3.6  
Consolidation  
TA 1.1±1.4  
C 2.6±2.2  
(P <0.5)  None  Induction 
(units)  
TA 22.1±13.2  
C 23.1±11.7  
Consolidation  
(units)  
TA 3.7±4.1  
C 9.3±3.3  
(P <0.5)  Therapeutic  
Non-randomized studies  
Ben-Bassat 
1990 [39] Not controlled  54 Newly diagnosed 
AML No 
thromboembolic 
events observed  Major bleeding 
6/78 induction 
courses  
Major bleeding 
0/53 
consolidation 
courses  
 1 death due to 
bleeding  Induction  
4.6 ± 4.1  
Consolidation 
1.7 ± 1.8 
transfusions  Therapeutic  
Sanz 2010 [40] Historical control  732 Induction APL 
patients  
 Tranexamic acid 
use RR 1.96 
 (P = 0.049)  Not reported  No difference 
5.1% (9 of 175). 
5% (28 of 561)  Not reported  Prophylactic  
>30 
 
Page 49 of 63 
 Table 3: Epsilon Amino caproic Acid Studies (Characteristics)  
Study  Type of 
study  No. 
of 
pts No. 
who 
rec’d 
EACA  No. plt 
refractory/ 
allo-
immunization  Diagnosis of 
patient  Treatment 
of 
underlying 
disease  EACA 
dose  EACA 
frequency  EACA 
route  Treatment 
started  Treatment 
stopped  Platelets 
given  
Randomized studies  
Gallardo 
1983 [23] RCT 19 9 NR 15 AML  
4 ALL  
(1 patient 
inevaluable)  Chemo  Loading 
dose 
100mg/kg  
12-24g/day 
thereafter  NR NR Platelet 
count < 20 
x 109/l Platelet 
count ≥ 20 x 
109/l Platelet 
count < 
20 x 109/l 
Non-randomized studies  
Wassenaar 
2008 [24] Control 
group  
Retro -
spective 
database 
analysis  30 17 NR 30 APL  
(No comparison 
made between 
those that 
received/did not 
receive EACA)  Chemo [30] 
 
(19 pre -
ATRA era)  
 Loading 
dose 6g  
Followed by 
1g/hr 
continuous 
infusion  Infusion  IV If α-2-
antiplasmin 
< 50%  If α-2-
antiplasmin 
> 50% for 2 
consecutive 
days  NR 
Ballen 
2004 [25] No control 
group  26 26 NR 14 Lymphoma  
8 MM  
4 Solid tumors  
 AutoSCT [26]  1 to 6g 
titrated 
upwards to 
treat 
bleeding  
Max dose 
24g/day  4 x /day  PO 
IV 
infusion 
if unable 
to 
tolerate 
PO Platelet 
count < 30 
x 109/l When 
thrombocyto
penia had 
resolved  25/26 
had none 
(religious 
reasons)  
Bartholom
ew 
1989 [2644] No control 
group  
 
 17 17 17 8 ITP  
2 MDS & ITP  
2 HIV  
1 AA  
1 CLL 
1 Drug induced 
thrombocytope
nia 
1 BSS  
1 Unknown  NR Loading 
dose 5g  
Then 1g  6 x /day.  
Decreased 
to 4x /day 
once 
bleeding 
stopped  14/17 
PO 
3/17 IV  
 To control 
bleeding.  
 
3/14 had 
platelet 
count > 20 
x 109/l prior 
to Rx  Platelet 
count 35 to 
50 x 109/l NR 
Benson 
1993 [27] No control 
group  
 
Retro -
spective  18 18 9 6 Solid tumors  
3 CML  
3 AML  
2 ALL  
4 Other  Auto SCT [8]  
AlloSCT [10]  0.5 to 
1.5g/hr  Infusion  IV To control 
severe 
bleeding  NR NR 
Brown 
2006 [28] No control 
group  48 48 NR 23 MM  
15 NHL  
8 HL  
2 Solid tumors  AutoSCT [48]  4g 6x /day  IV Platelet 
count < 30 
x 109/l NR None 
(religious 
reasons)  
 
 
 
 
 
             
 
Page 50 of 63 
 AA = aplastic anemia  
AlloSCT = allogeneic stem cell transplant  
AML = acute myeloid leukemia  
AutoSCT = autologous stem cell transplant  
ALL = acute lymphocytic leukemia  
APL = acute prolymphocytic  leukemia  
ATRA = All Trans Retinoic Acid  
BSS = Bernard Soulier Syndrome  
Chemo = chemotherapy  
CLL = chronic lymphocytic leukemia  
CML = chronic myeloid leukemia  CNS = central nervous system  
CTCAE = common toxicity criteria adverse events  
GI = gastrointestinal  
Hb = hemoglobin  
HL = Hodgkin’s lymphoma  
ICH = intra -cranial hemorrhage  
ITP = immune thrombocytopenia  
IV = intravenous  
MDS = myelodysplastic syndrome  
MM = Multiple myeloma  
Mth = month  NHL = non -Hodgkin’s  lymphoma  
NR = not reported  
Ped = ped iatric  
Plt = platelet  
PO = oral  
Pt = patient  
RBC = red blood cell  
Rx = treatment  
Tx = transfusion  
VTE = venous thromboembolism   
Table 3. 
Continued  
 
Study  Type of 
study  No. 
of 
pts No. 
who 
rec’d 
EACA  No. platelet 
refractory/ 
allo-
immunization  Diagnosis of 
patient  Treatment 
of 
underlying 
disease  EACA 
dose  EACA 
frequency  EACA 
route  Treatmen
t started  Treatment 
stopped  Platelets 
given  
Chakrabati 
1998 [29] No control 
group  15 15 NR 4 AML  
4 ALL  
5 ITP  
2 AA  NR Major 
bleeding  
Loading 
dose 5g 
then 1g  
 
Minor 
bleeding  
250mg  Major 
bleeding  
 4 x /day 
increased to 
6x /day if no 
response  
 
4 x /day  NR Platelet 
count < 20 
x 109/l and 
bleeding  NR If no 
response 
to 6g 
EACA 
per day  
Gardner 
1980 [30] No control 
group  14 
(4 
Ped)  14 At least 2  9 AA  
1 AML  
1 ALL  
1 Myelofibrosis  
2 Other  NR 8 to 24g/day 
in adult 
patients  Varied.  
 
Up to 13 
months of 
Rx.  IV or PO  To control 
bleeding  Platelet 
count > 20 x 
109/l Therape
utic 
Garewal 
1985 [31] No control 
group  9 9 8 4 AML  
2 ALL  
1 CLL  
1 MDS  
1 Other  
(Excluded 
APL)  NR Loading 
dose 5g  
Then 4g  6 x /day 
(decreased 
to 3 to 4 
x/day if 
higher dose 
not 
tolerated)  IV or PO  Platelet 
count < 20 
x 109/l NR NR 
Kalmadi 
2006 [11] Retro -
spective 
database 
analysis of 
patients 
receiving 
EACA  
Only pts > 
18yrs & plt 
count < 75 
x 109/l 
No control 
group  77 77 32 22 AML  
20 MDS (11 
transforming to 
AML)  
10 NHL  
6 CML  
4 ALL 
2 AA  
2 ITP  
2 Myelofibrosis  
1 CLL  
1 MM  
7 Solid tumors  NR Median 
initial dose 
4g/day 
(range 2g to 
24g/day).  
 
Median 
dose 6g/day  
(range 2g to 
24g/day).  
 NR NR Median plt 
count 7 x 
109/l (range 
1 to 66 x 
109/l). 
 Median 
duration of 
treatment 8 
days (range 
1 to 216 
days)  NR 
 
Page 51 of 63 
 Table 4: Epsilon Amino caproic Acid Studies (Results)  
 
Study  Type of study  No. of 
pts Diagnosis of patient  Thrombotic risk  Bleeding  Death due to bleeding  Platelet transfusions  Platelets 
given  
Randomized studies  
Gallardo 
1983 [23] RCT 19 15 AML  
4 ALL  No deaths due to 
thromboembolic 
disease  Capillary bleeding  
EACA 31% of days at risk*  
Placebo 50% of days at risk*  
Major bleeding†  
EACA 15%  
Placebo 19%  NR EACA  
1 every 13.3 days at 
risk* 
Placebo  
1 every 10.5 days at 
risk* Prophylactic  
Non-randomized studies  
Wassenaar 
2008 [24] Control group  30 30 APL  
 1 episode of catheter 
assoc. 
thromboembolism. No 
effort to identify 
asymptomatic episodes 
of VTE  No CTCAE grade 4 bleeding  
Grade 3 bleeding [9]  
Grade 2 bleeding [3]  
Grade 1 bleeding [5]  None  NR NR 
Ballen 2004 [25] No control group  26 14 Lymphoma  
8 MM  
4 Solid tumors  
 NR 5/26 bled  
2 life -threatening (1 died)  
1 nasal packing  
2 minor  
No bleeding when  plt count > 5 
x 109/l 1 Died ICH (D7) CNS 
disease 
(medulloblastoma)  1 patient with ICH  25/26 had 
none 
(religious 
reasons)  
Bartholomew 
1989 [26] No control group  17 8 ITP  
2 MDS & ITP  
2 HIV  
1 AA  
1 CLL  
1 Drug induced 
thrombocytopenia  
1 BSS  
1 Unknown  NR All bled prior to EACA.  
1/17 Bleeding stopped  
16/17 Bleeding controlled  
 1 Died ICH (ICH 
present prior to EACA 
administration)  Platelet use decreased 
from 164 units in 8/12 
period prior to EACA to 
18 units in 4/12 period 
following 
administration of drug  NR 
Benson 
1993 [27] No control group  18 6 Solid tumors  
3 CML  
3 AML  
2 ALL  
4 Other  
 No thrombotic events  Bleeding markedly 
reduced/stopped 12/18  
 
No response 6/18  NR NR NR 
Brown 2006 [28] No control group  48 23 MM  
15 NHL  
8 HL  
2 Solid tumors  
 NR 1 Major GI bleed  None  None  None 
(religious 
reasons)  
Chakrabati 
1998 [29] No control grou p 15 4 AML  
4 ALL  
5 ITP  
2 AA NR Prior to EACA 10/15 had major 
bleeding and 5/15 minor 
bleeding.  
During EACA  
8/10 with major bleeding 
stopped bleeding  
2/10 stable Hb. 5/5 with minor None  NR If no 
response to 
6g EACA 
per day  
 
Page 52 of 63 
 bleeding stopped bleeding  
 
Study  Type of study  No. of 
pts Diagnosis of patient  Thrombotic risk  Bleeding  Death due to bleeding  Platelet transfusions  Platelets 
given  
Chakrabati 
1998 [29] No control group  15 4 AML  
4 ALL  
5 ITP  
2 AA  NR Prior to EACA 10/15 had major 
bleeding and 5/15 minor 
bleeding.  
During EACA  
8/10 with major bleeding 
stopped bleeding  
2/10 stable Hb. 5/5 with minor 
bleeding stopped bleeding  
 None  NR If no 
response to 
6g EACA 
per day  
Gardner 
1980 [30] No control group  13 9 AA  
1 AML  
1 ALL  
1 Myelofibrosis  
1 Other  No thromboembolic 
events observed  Not reported for all patients.  
 
Text reports decreased 
bleeding  None  Platelet usage 
reported for 4/13 
receiving long term 
EACA (> 5 mths).  
 
Before EACA 30units 
plts/pt/mth  
During EACA  
1unit plts/pt/mth  
 Therapeutic  
Garewal 
1985 [31] No control group  9 4 AML  
2 ALL 
1 CLL  
1 MDS  
1 Other  No thromboembolic 
events observed  All bled prior to EACA.  
 
3 bled  during EACA  2 Died ICH (D8; D21)  
1 Died bleeding peptic 
ulcer (D29)  
(All had progressive 
disease unresponsive 
to treatment)  NR NR 
Kalmadi 
2006 [11] Retrospective 
database 
analysis  
 
No control group  77 22 AML  
20 MDS (11 
transforming to AML)  
10 NHL  
6 CML  
4 ALL  
2 AA  
2 ITP  
2 Myelofibrosis  
1 CLL  
1 MM  
7 Solid tumors  NR 51 bleeding stopped  
 
13 reduced RBC requirements 
by > 50% compared to previous 
3/7 
 
13 no response  
 NR Before EACA mean 
1.5 ± 0.8 plt Tx/day  
 
During EACA mean 
1.0 ± 0.7 plt Tx/day  
 
(P < 0.0001 t test)  NR 
* Days at risk defined as days when platelet count less than 20 x 109/l 
† Major bleeding defined as nose bleeding requiring posterior packing, gross gastrointestinal or genitourinary tract bleeding and central nervous system bleeding  
NR = not reported  
 
 
 
 
 
 
 
 
 
 
Page 53 of 63 
  
 
Table 5: Prophylactic use of Tranexamic acid vs. Epsilon Aminocaproic Acid in RCTs.  
Organized in order of increasing ratios TXA vs. EACA.  
(Data from Henry et al 2011 [8]). 
 
Study  Number of 
participants  Study group  Dose  
Assume median weight 80kg (PLADO data)  Effect  
TXA EACA   TXA EACA  Ratio  Blood loss 
(mls). Random 
mean 
difference  Exposure to 
blood  
Dalmau 
2000 [32] 42 42 Orthotopic liver 
transplantation  16mg/kg/hr  16mg/kg/hr  1:1 Not reported  Not reported  
Dalmau 
1999 [33] 42 42 Orthotopic  liver 
transplantation  10mg/kg/hr  16mg/kg/hr  1.6:1  Not reported  No difference. 
Trend to TXA  
0.81 (0.64 to 1.02)  
Fergusson 
2008 [34] 770 780 High risk cardiac 
surgery patients  30mg/kg loading dose  
16mg/kg maintenance  
2mg/kg bypass circuit  
TOTAL = 3.84g  10g loading dose and 2g 
maintenance  
 
TOTAL = 12g  3.125:1  Not reported  No difference  
1.0 (0.93 to 1.07)  
Camarasa 
2006 [35] 35 32 Total knee 
replacement  10mg/kg over 30mins 
followed by 10mg/kg for 
3 hrs  
TOTAL = 3.2g  100mg/kg over 30mins 
followed by 1g/hr for 
3hrs 
TOTAL = 11g  3.44:1  No difference. -9 (-
270.16 to 252.16)  No difference. 
Trend to TXA  
0.23 (0.03 to 1.94)  
Casati 1999 [36] 72 68 Cardiac surgery  
(assume 3.5 hr 
op) 1g over 20 mins 
followed by 400mg/hr 
and 500mg pump prime  5g over 20mins followed 
by 2g/hr and 2.5g added 
to pump prime  5:1 Favours TXA. -
156.00 ( -234.25 to 
-77.75)  No difference  
0.7 (0.41 to 1.18)  
Menichetti 
1996 [37] 24 24 Cardiac surgery  
(assume 3.5hr op)  10mg/kg bolus then 
3mg/kg/hr. Additional 
10mg/kg to prime  
TOTAL = 2.44g  80mg bolus, 30mg/kg/hr. 
Additional 80mg/kg to 
prime  
TOTAL = 14.88g  6:1 Favours EACA. 
225.0 (36.28 to 
413.72)  Favours EACA  
 
Maineri 
2000 [38] 24 24 Cardiac surgery  
(assume 3.5 hr 
op) 20mg/kg over 60 mins 
then 2mg/kg/hr  
TOTAL = 2g  10g over 30mins 
followed by 2g/hr  
TOTAL = 16g  8:1 No difference. -40 
(-206.73 to 126.73)  No difference  
Landymore 
1997 [39] 56 44 Cardiac surgery  
(assume 3.5 hr 
op) 10mg/kg/hr followed by 
1mg/kg/hr  
TOTAL = 1.08g  5g followed by 1g/hr  
 
TOTAL = 8.5g  8.5:1  Favours EACA/ 
192 (65.87 to 
318.13)  Not reported  
Pinosky 
1997 [40] 20 20 Cardiac surgery  15mg/kg followed by 
1mg/kg/hr for 6 hrs  
TOTAL = 1.68 g 150mg/kg/hr followed by 
10mg/kg/hr for 6 hrs  
TOTAL = 16.8g  10:1 Favours TXA.  -
361 ( -666.56 to -
55.4)  No difference. 
Trend to EACA  
1.57 (0.77 to 3.22)  
Penta de 
Peppo 1995 [41] 15 15 Cardiac surgery  10mg/kg followed by 
1mg/kg for 10hr  
TOTAL = 1.6g  10g followed by 2g/hr for 
5 hrs  
TOTAL = 20g  12.5:1  No difference. 25 ( -
138.86 to 188.86)  No difference. 
Trend to TXA  
0.33 (0.04 to 2.85)  
 
 Figure 1: Fergusson Trial 2008 (BART trial). Comparison of outcomes between TXA and EACA  
 
 
 
 
 
 
 

 
 Figure 2: Fergusson Trial 2008 (BART). Comparison of adverse events between TXA and EACA.  
 
 
 

 
 APPENDIX 2: WHO GRADING SYSTEM  
General Definitions of WHO Grades  
 
Grade 1  Any bleeding that does not fulfil the criteria for Grade 2 bleeding (general or organ -specific).  For examples of grade 1 
bleeding, please see organ -specific definitions.  
Grade 2  Any bleeding that does not fulfil the criteria for Grade 3 bleeding (general or organ -specific) BUT requires an intervention or 
treatment:  
• Examples of interventions  
▪ Nasal packing  
▪ Bladder irrigation  
• Examples of treatments  
▪ Platelet transfusion given to treat active bleeding and NOT given only because the platelet count is below the 
prophylactic platelet transfusion trigger  
▪ Medications prescribed to treat bleeding  
Grade 3  Any bleeding  that does not fulfil the criteria for Grade 4 bleeding (general or organ -specific) BUT requires:  
• Red cell transfusion specifically related to treatment of bleeding within 24 hours of onset of bleeding, for example:  
▪ Required to treat fall in hemoglobin of at least 2 g/dL within preceding 24 hours without evidence of hemolysis  
▪ No hemoglobin increment within 24 hours of at least a 2 unit red cell transfusion without evidence of hemolysis  
• A significant intervention, for example:  
▪ Endoscopy to treat the bleeding  
▪ Interventional radiography to treat the bleeding  
▪ Transfer to the operating room for treatment of bleeding  
Grade 4  Any bleeding that is:  
• Fatal  
• Life-threatening. For example:  
▪ Bleeding that requires transfer to intensive care/treatment unit  
▪ Bleeding that is associated with hemodynamic instability and causes inadequate tissue perfusion, including:  
❖ Hypotension  
o Systolic blood pressure (BP) < 90 mmHg  
o > 40 mmHg fall in systolic BP  
o Mean arterial pressure (MAP) < 65 mmHg  
❖ In absence of hypotension, markers of inadequ ate tissue perfusion include:  
o Increased blood lactate  
o Increased base deficit  
o Perfusion related low pH (if other causes of metabolic acidosis (e.g. sepsis) are not present)  
 
 Organ -specific definitions of WHO Grades  
 Grade 1  Grade 2  Grade 3  Grade 4  
General  Bleeding that does not fulfil the 
requirements for grade 2 
bleeding. Please see examples 
in organ -specific categories 
below.  Any bleeding that does not fulfil 
the requirements for grade 3 
bleeding BUT requires an  
intervention or treatment:  
Example s of Interventions  
- Nasal Packing  
- Bladder irrigation  
Examples of treatments  
- Platelet transfusion given to 
treat active bleeding and NOT 
given only because the platelet 
count is below the prophylactic 
platelet transfusion trigger  
- Medications prescribed to treat 
bleeding  
 Any bleeding that does not fulfil 
the criteria for grade 4 bleeding  
BUT requires:  
Red cell transfusion specifically 
related to treatment of bleeding 
within 24 hours of onset of 
bleeding.  
OR 
A significant intervention, for 
example:  
- Endoscopy to treat the bleeding  
- Interventional radiography to 
treat the bleeding  
- Transfer to the operating 
theatre/ room for treatment of 
bleeding  
 Any bleeding that is fatal or life 
threatening. For example:    
- Bleeding that requires transfer 
to intensive care/treatment unit  
- Bleeding that is associated 
with hemodynamic instability 
and causes inadequate tissue 
perfusion  
(for further clarification see 
general guideline above).  
 
Oral and nasal†  Spontaneous oropharyngeal 
bleeding - total duration of all 
episodes in previous 24 hours < 
30 minutes*  
 
Traumatic oropharyngeal 
bleeding e.g. after bites to li ps 
and tongue lasting > 10 minutes 
or interfering with daily activities  
 
Epistaxis - total durati on of all 
episodes in previous 24 hours < 
30 minutes*  
 
Petechiae of oral mucosa  
 
Few (≤ 5) hemorrhagic bullae or 
blisters  Oropharyngeal bleeding – total 
duration of all episodes in 
previous 24 hours > 30 minutes*  
 
 
 
 
 
 
Epistaxis – total duration of all 
episodes in previous 24 hours > 
30 minutes*  
 
 
 
Multiple (> 5) hemorrhagic bullae 
or blisters  Any bleeding that requires a 
transfusion or a procedure (not 
including intubation)  Any bleeding that requires 
intubation to protect the airway  
Skin†  Few (≤ 5) spontaneous bruises  
(ecchymoses) over 2.5cm in size 
and none >10cm  
 
 
 
 
 
Purpura (3mm to 10mm 
diameter) (Few purpuric lesions Multiple (> 5) spontaneous 
bruises (ecchymoses) each 
>2.5cm or any one >10cm.  
 
Many (> 10) spontaneous 
bruises (ecchymoses) (>10mm in 
diameter)  that does not fulfil the 
above criteria.  
 
Purpura (3mm to 10mm Any bleeding that requires a 
transfusion or a procedure   
 
 (≤ 10).  
 
 
Petechiae (< 3mm diameter) 
covering ≤ 25% of skin (1 arm = 
10%; 1 leg = 25%; trunk = 44%; 
head = 6%)  diameter). Many purpuric lesions 
(> 10).  
 
 
Petechiae covering >  25% of skin 
(1 arm = 10%; 1 leg = 25%; trunk 
= 44%; head = 6%).  
Soft-tissue and 
musculoskeletal  Asymptomatic spontaneous soft -
tissue hematoma less than 10cm 
in diameter.  
 
 
 
Traumatic joint bleeding 
(confirmed by aspiration, imaging 
study or other accepted 
technique)  Asymptomatic  spontaneous soft -
tissue hematoma greater than 
10cm in diameter.  
 
Symptomatic soft -tissue 
hematoma (e.g. causing pain or 
discomfort).  
 
Spontaneous joint bleeding 
(confirmed by aspiration, imaging 
study or other accepted 
technique)  
 Any bleeding that requires a 
transfusion or a procedure (not 
including compartment 
syndrome)  Any bleeding that causes 
compartment syndrome.  
 
 
Gastrointestinal  Fecal occult blood  
 
Rectorrhagia - visible red blood 
on tissue paper/not mixed with 
stool  Melena  
 
Hematochezia – visible red blood 
mixed in stool, not requiring a 
transfusion  
 
Hematemesis – Grossly visible 
blood in emesis (vomit) or in 
nasogastric drainage tube (not 
related or  
secondary to swallowed blood)  Rectal Bleeding requiring a 
transfusion  
 
Hematemesis requiring a 
transfusion  
 
Any bleeding that requires a 
transfusion or a procedure   
Genitourinary  Abnormal vaginal bleeding 
(Unexpected bleeding out of 
normal cycle OR Bleeding  
heavier than normal OR  
Breakthrough bleeding (patient 
on hormonal therapy to prevent  
bleeding)) with spotting  
 
 Abnormal vaginal bleeding 
(Unexpected bleeding out of 
normal cycle OR Bleeding 
heavier than normal OR 
Breakthrough bleeding (patient 
on hormonal therapy to prevent 
bleeding)) more than spotting  
 
Gross/visible hematuria  
 
 
 Any bleeding that causes:  
increase ≥1.5 X reference serum 
creatinine ǂ 
or 
Serum creatinine rises by ≥ 
26µmol/L (0.3mg/dl) withi n 48 
hours 
 
or 
Urine output <0.5 mL/kg/hr for > 
6 consecutive hrs  
 
Or  
Any bleeding that requires a 
transfusion or a procedure  Any bleeding that causes:  
increase ≥3 X reference serum 
creatinine ǂ 
or  
Serum creatinine rises by ≥354 
μmol/L (4.0 mg/dl)  
or  
Commenced on renal 
replacement therapy  
or  
Urine output <0.3 mL/kg/ hr for 
> 24 hrs  
or  
Anuria for at least 12 hrs  
Pulmonary   Hemoptysis – Visible blood  
 Any bleeding requiring 
supplemental oxygen to maintain Any bleeding requiring 
respiratory support (includes 
 
 Blood in broncho -pulmonary 
lavage, or blood tinged sputum  
(excluding  those with nose or 
oropharyngeal bleeding or 
mucositis).  oxygen saturation above 93%.  
 non-invasive (CPAP, BiPAP), 
or invasive ventilation)  
Body c avity   Visible blood in body cavity fluid 
(e.g. red cells apparent in fluid 
aspirate) short of criteria for 
Grade 3 or 4  Grossly visible blood in body 
cavity fluids AND organ 
dysfunction with symptoms, 
AND/OR need to intervene (e.g. 
to aspirate).  
 
Any bleeding that requires a 
transfusion or a procedure   
Eye†  Sub-conjunctival hemorrhage   
 
 
Traumatic retinal bleeding 
without visual impairment  
 
 
Traumatic vitreous bleeding 
without visual impairment  Diffuse sub -conjunctival 
hemorrhage in both eyes  
 
Spontaneous retinal bleeding 
without visual impairment  
 
 
Spontaneous vitreous bleeding 
without visual impairment   
 
 
Retinal bleeding with temporary 
visual impairment ** (present for 
≤ 7 days)  
 
Vitreous bleeding with temporary 
visual impairment *** (present  for 
≤ 7 days)   
 
 
Retinal bleeding with 
permanent visual impairment ** 
(present for > 7 days)  
 
Vitreous bleeding with 
permanent visual impairment ** 
(present for > 7 days)  
Central nervous 
system   Lumbar puncture with blood (>5 
RBC/μL  in CSF on microscopic 
analysis and non -traumatic tap),  
no neurological symptoms and 
no  visible red color  
 
Traumatic CNS bleeding on 
imaging study without 
neurological dysfunction  Lumbar puncture with visible red 
color in absence of neurological 
symptoms, and non -traumatic 
tap 
 
 
 
Spontaneous CNS bleeding on 
imaging study without 
neurological dysfunction  CNS symptoms with non -
traumatic bloody lumbar 
puncture  
 
 
 
 
CNS bleeding on imaging study 
with neurological dysfunction  
Invasive sites  Bleeding at invasive sites or sites 
of minor trauma (e.g. 
venipuncture sites, intravenous 
lines or catheter exit sites): active 
oozing at site for > 10 minutes  Bleeding at invasive sites  
(venipuncture sites, intravenous 
lines or catheter exit sites): active 
oozing at site for a cumulative 
total of > 1 hour in the previous 
24 hours.  Any bleeding that requires a 
transfusion or a procedure   
 
*Count actual bleeding (i.e. “running out” or need for basin, tissue, towel, etc.) not minor  bleeding  
**Visual impairment is defined as a field deficit, and patients with suspected visual impairment require an ophthalmological consultation  
*** Visual impairment confirmed by ophthalmological consultation  
†  Petechiae  of oral mucosa and skin  
    Subconjunctival hemorrhage  
    Hemorrhagic bullae/blisters in mouth  
    Purpura and ecchymoses  
These are all documented as bleeding on the 1st day they are seen and any subsequent day that the bleeding is worse than the preceding day. If the bruising / petechiae is 
the same as or not as severe as the previous day it will not be counted as bleeding [For discussion].  
 
   
ǂ Reference serum creatinine  is the baseline serum creatinine result taken on entry into the study  
Definitions of Bleeding Signs  
 
Definition of bleeding signs based on physical examination  
Site of bleeding  Sign  Definition  
Skin (epidermis and 
dermis)    
        Petechiae  Red (recent) or purplish (a few days old) spot discoloration in the skin with a 
diameter between 0.5 mm to < 3 mm, not blanching  with pressure and not palpable  
 Purpuric macule 
(purpura)  Differentiated from petechiae only for their larger size between 3 to 1 0 mm.  
 Ecchymosis 
(bruise or 
contusion)  Larger than 10mm in size. Flat, rounded or irregular, red, blue, purplish or yellowish 
green patches, larger than a petechia or purpura. If elevated they represent 
superficial spreading of an underlying hematoma  
Skin (subcutaneous tissue)    
 Hematoma  Bulging localized accumulation of blood often with discoloration of overlying skin  
Visible mucous 
membranes    
 Petechia, 
purpuric  
macules and 
ecchymoses  As for skin  
 Bulla/ vesicle  
(Blister)  Visible raised, thin -walled, circumscribed lesions containing  blood.  
Bullae (≥ 5mm) are larger than vesicles  (< 5 mm).  
They should be counted together as bullae  
 Epistaxis  Any bleeding from the nose, may be anterior or posterior and unilateral or bilateral  
 Gingival 
bleeding  Any bleeding from the gingival margins  
 Subconjunctival 
hemorrhage  Bright red discoloration underneath the conjunctiva at onset then same color 
changes as ecchymoses  
Muscles and soft tissues    
 Hematoma  Any localized collection of blood , visible  or palpable or revealed by imaging. May be 
dissecting when spreading along fascial spaces  
 
 
 Appendix 3:       A-TREAT  Telephone Script: Long -Term Follow -Up 
To be performed at 30 days post discontinuation of study drug & 120 days post activation  of study drug  
 
Assessment Time Point :   
 30 days post discontinuation of study drug  
 120 days post activation  of study drug  
 
 No answer/patient unavailable:  
  No voicemail/message left - local physician will be contacted for medical records  
  Left voicemail/message:  
 
 Made contact with patient:  
 
Recommended Introduction : My name is [ name of CRC, Research Nurse or Investigator ] and I am 
calling from [ study site ] for a quick follow up regarding the A-TREAT  clinical trial you recently 
participated in.  I have a few questions to ask that will help our team understand how you’re doing 
after treatment:  
 
• How are you feeling?  
• Have you experienced any health problems si nce the last time someone from the study team 
spoke with you?  
• Have you experienced, or are you currently experiencing, any of the following:  
 
 swelling in your arms or legs  
Comme nt: 
 
 shortness of breath  
Comment:   
 
D30 Patient Reminders and Recommended Closing Comments : Just a reminder that we will call for 
your last study follow -up on [ date of D 120]. Thank you for your time and further participation, please 
don’t hesitate to contact us at [ phone number, email address, clinic name ] if you have any questions or 
concerns regarding the study.   
 
D120 Recommended Closing Comments : Thank you for your partici pation in this study - today was the 
last scheduled follow -up, but please feel free to contact us at [ phone number, email address, clinic 
name ] with any quesitons or concerns regarding the study.  
 
 
 
 
Signature:  Date and Time of Call:  
A-TREAT  Follow -Up: Telephone Script   Protocol Version Date: 0 6-JAN-2016 
  
 
 CITATIONS  
 
1 Heddle NM, Cook RJ, Sigouin C, et al. A descriptive analysis of international transfusion practice and bleeding 
outcomes in patients with acute leukemia. Transfu sion 2006; 46:903 -911. 
2 Gmur J, Burger J, Schanz U, et al. Safety of stringent prophylactic platelet transfusion policy for patients with 
acute leukemia. Lancet 1991;338:1223 -1226  
3 Gil-Fernandez JJ, Alegre A, Fernandez -Villalta MJ, et al. Clinical result s of a stringent policy on prophylactic 
platelet transfusion: Non -randomized comparative analysis in 190 bone marrow transplant patients from a single 
institution. Bone Marrow Transplant 1996;18:931 -935. 
4 Slichter SJ, Kaufman RM, Assman SF, et al. Dose of  prophylactic platelet transfusions and prevention of 
hemorrhage. N Engl J Med 2010;362:600 -13. 
5 Wandt H, Schaefer -Eckart K, Wendelin K, et al. Therapeutic platelet transfusion versus routine prophylactic 
transfusion in patients with haematological malign ancies: an open -label, multicenter, randomized study. The 
Lancet 2012;380(9850):1309 -1316.  
6 Stanworth SJ, Estcourt L, Powter G, et al. A No -Prophylaxis Platelet -Transfusion Strategy for Hematologic 
Cancers. N Engl J Med 2013;368:1771 -80 
7 Slichter  SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfusion 
Medicine Reviews 2004;18:153 -167. 
8 Henry DA, Moxey AJ, Carless PA, et al. Anti -fibrinolytic use for minimizing perioperative allogeneic blood 
transfusion.  Cochrane Database Syst Rev 2001; 1:CD001886.  
9 Ghosh K, Shetty S, Jijina F, Mohanty D. Role of epsilon aminocaproic acid in the management of haemophilic 
patients with inhibitors. Haemophilia 2004; 10:58 -62. 
10 Brown NM, Matthews B, Ford PA. Treatment of a  Jehovah’s Witness using a transfusion -free autologous stem 
cell transplant protocol. Comm Onc 2006;3:776 -780. 
11 Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M. Epsilon aminocaproic acid reduces transfusion requirements in 
patients with thrombocytopenic hemor rhage. Cancer 2006; 107:136 -140. 
12 Shpilberg O, Blumenthal R, Sofer O, et al. A controlled trial of tranexamic acid therapy for the reduction of 
bleeding during treatment of acute myeloid leukemia. Leukemia and Lymphoma 1995;19:141 -144.  
13 Report of the US  Department of Health and Human Services. The 2009 national blood collection and utilization 
survey report . Washington, DC:US Department of Health and Human Services, Office of the Assistant Secretary 
for Health, 2011.  
14 Blajchman MA, Bordin JO, Bardossy L , Heddle NM. The contribution of the haematocrit to thrombocytopenic 
bleeding in experimental animals. Br J Haematol 1994; 86:347 -50.  
15 Lethagen S. Desmopressin (DDAVP) and hemostasis. Ann Hematol 1994;69:173 -180. 
16 Hennewig U, Laws HJ, Eisert S, Gobel U.  Bleeding and surgery in children with Glanzmann Thrombasthenia 
with and without the use of recombinant Factor VIIa. Klin Pädiatr 2005; 217:365 -370. 
17 Ghosh K, Shetty S, Jijina F, Mohanty D. Role of epsilon aminocaproic acid in the management of haemophili c 
patients with inhibitors. Haemophilia 2004; 10:58 -62. 
18 Estcourt LJ, Heddle NM, Cook RJ, et al.  A descriptive analysis of international transfusion practice and  
bleeding outcomes in patients with acute leukemia. Transfusion  2006;46:903 -911. 
19 Avvisati G1, ten Cate JW , Büller HR , Mandelli F . Tranexamic acid for control of haemorrhage in acute 
promyelocytic leukaemia. Lancet.  1989 Jul 15;2(8655):122 -4. 
20 Fricke W1, Alling D, Kimball J, et al. Lack of eff icacy of tranexamic acid in thrombocytopenic bleeding. 
Transfusion. 1991 May;31(4):345 -8. 
21 Ben-Bassat I, Douer D, Ramot B. Tranexamic acid in acute myeloid leukemia: possible reduction of platelet 
transfusions. Eur J Haematol  1990;45:86 -89. 
22 Sanz MA, Mon tesinos P. Open issues on bleeding and thrombosis in acute promyelocytic leukemia. Thromb 
Res 2010;125 Suppl 2:S51 -4. 
23 Gallardo RL, Gardner FH. Antifibrinolytic therapy for bleeding control during remission induction for acute 
leukemia. Blood 1983; 62:202 a. 
24 Wassenaar T, Black J, Kahl B, et al. Acute promyelocytic leukaemia and acquired α -2-plasmin inhibitor 
deficiency: a retrosdpective look at the use of epsilon -aminocaproic acid (Amicar) in 30 patients. Hematol Oncol 
2008;26:241 -246. 
25 Ballen KK, Becker  PS, Yeap BY, et al. Autologous bone marrow transplantation can be performed safely 
without the use of blood -product support. J Clin Oncol  2004; 22:4087 -4094.  
26 Bartholomew JR, Salgia R, Bell WR. Control of bleeding in patients with immune and nonimmune 
thrombocytopenia with aminocaproic acid. Arch Intern Med 1989;149:1959 -1961.  
 
 
  
27 Benson K, Fields K, Hiemenz J, et al. The platelet -refractory bone marrow transplant patient: prophylaxis and 
treatment  of bleeding. Sem Onc 1993;5 suppl 6:102 -109. 
28 Brown, NM, Matthews B, Ford PA. Treatment of a Jehovah’s Witness using a transfusion -free autologous stem 
cell transplant protocol. Comm Onc 2006;3:7760781.  
29 Chakrabarti S, Varma S. Low dose bolus Aminocapro ic acid: an alternative to platelet transfusion in 
thrombocytopenia? Eur J Haematol. 1998;60:313 -314. 
30 Gardner GH, Helmer RE. Aminocaproic Acid: Use in control of hemorrhage in patients with amegakaryocytic 
thrombocytopenia. JAMA 1980; 243:35 -37. 
31 Garewa l HS, Durie BGM. Anti -fibrinolytic therapy with aminocaproic acid for the control of bleeding in 
thrombocytopenic patients. Scand J Haematol 1985;35:497 -500. 
32 Dalmau A, Sabate  A, Acosta F, et al. Tranexamic acid reduces red cell transfusion better than epsilon -
aminocaproic acid or placebo in liver transplantation. Anesthesia & Analgesia 2000;91(1):29 -34. 
33 Dalmau A, Sabate A, Acosta F, et al. Comparative study of antifibrinolyt ic drugs in orthotopic liver 
transplantation. Transplantation Proceedings 1999;31(6):2361 -2. 
34 Fergusson DA, Hébert PC, Mazer CD, et al. A comparison of aprotinin and lysine analogues in high -risk cardiac 
surgery. The New England Journal of Medicine 2008;3 58(22):2319 -31. 
35 Camarasa MA, Olle G, Serra -Prat M, et al. Efficacy of aminocaproic, tranexamic acids in the control of bleeding 
during total knee replacement: a randomized clinical trial. British Journal of Anaesthesia 2006;96(5):576 -82. 
36 Casati V, Guzz on D, Oppizzi M, et al. Hemostatic effects of aprotinin, tranexamic acid and epsilon -
aminocaproic acid in primary cardiac surgery. Annals of Thoracic Surgery 1999;68(6):2252 -6. 
37 Menichetti A, Tritapepe L, Ruvolo G, et al. Changes in coagulation patterns, blood loss and blood use after 
cardiopulmonary bypass: aprotinin vs tranexamic acid vs epsilon aminocaproic acid. Journal of Cardiovascular 
Surgery 1996;37(4):401 -7. 
38 Maineri P, Covaia G, Realini M, et al. Postoperative bleeding after coronary revasculari zation. Comparison 
between tranexamic acid and epsilon -aminocaproic acid. Minerva Cardioangiologica 2000;48(6):155 -60. 
39 Landymore RW, Murphy JT, Lummis H, Carter C. The use of low -dose aprotinin, epsilon -aminocaproic acid or 
tranexamic acid for prevention  of mediastinal bleeding in patients receiving aspirin before coronary artery bypass 
operations.. European Journal of Cardio -Thoracic Surgery 1997;11:798 -800. 
40 Pinosky ML, Kennedy DJ, Fishman RL, et al.  Tranexamic acid reduces bleeding after cardiopulmona ry bypass 
when compared to epsilon aminocaproic acid and placebo. Journal of Cardiac Surgery 1997;12::330 -8. 
41 Penta de Peppo A, Pierri MD, Scafuri A, et al. Intraoperative antifibrinolysis and blood -saving techniques in 
cardiac surgery. Prospective trial of 3 antifibrinolytic drugs. Texas Heart Institute Journal 1995;22::231 -6. 